US20080183239A1 - Breathing therapy device and method - Google Patents
Breathing therapy device and method Download PDFInfo
- Publication number
- US20080183239A1 US20080183239A1 US11/981,727 US98172707A US2008183239A1 US 20080183239 A1 US20080183239 A1 US 20080183239A1 US 98172707 A US98172707 A US 98172707A US 2008183239 A1 US2008183239 A1 US 2008183239A1
- Authority
- US
- United States
- Prior art keywords
- breathing
- stimulation
- diaphragm
- rate
- protocol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000029058 respiratory gaseous exchange Effects 0.000 title claims abstract description 156
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002560 therapeutic procedure Methods 0.000 title claims description 24
- 230000000638 stimulation Effects 0.000 claims abstract description 142
- 230000000241 respiratory effect Effects 0.000 claims abstract description 51
- 208000008784 apnea Diseases 0.000 claims abstract description 36
- 230000004936 stimulating effect Effects 0.000 claims abstract description 25
- 238000009423 ventilation Methods 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 21
- 230000004913 activation Effects 0.000 claims description 18
- 230000003247 decreasing effect Effects 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 11
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000037007 arousal Effects 0.000 claims description 7
- 238000006213 oxygenation reaction Methods 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 238000001994 activation Methods 0.000 claims 17
- 230000003190 augmentative effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 206010019280 Heart failures Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000007634 remodeling Methods 0.000 abstract description 3
- 208000019693 Lung disease Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000000414 obstructive effect Effects 0.000 abstract description 2
- 230000002269 spontaneous effect Effects 0.000 description 35
- 238000002567 electromyography Methods 0.000 description 27
- 230000033001 locomotion Effects 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 230000036387 respiratory rate Effects 0.000 description 14
- 230000003797 telogen phase Effects 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 108091008690 chemoreceptors Proteins 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 208000000122 hyperventilation Diseases 0.000 description 7
- 230000000870 hyperventilation Effects 0.000 description 7
- 210000000412 mechanoreceptor Anatomy 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 108091008704 mechanoreceptors Proteins 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000001034 respiratory center Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 108091008709 muscle spindles Proteins 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000003019 respiratory muscle Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001515 vagal effect Effects 0.000 description 3
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000003105 phrenic nerve Anatomy 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002413 aortic body Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000001011 carotid body Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004699 muscle spindle Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003504 pulmonary stretch receptor Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000009064 short-term regulation Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36132—Control systems using patient feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3601—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
- A61B5/395—Details of stimulation, e.g. nerve stimulation to elicit EMG response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/389—Electromyography [EMG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4818—Sleep apnoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
Definitions
- the invention relates to a device and method for detection, diagnosis and treatment of breathing disorders and to the management of pulmonary or cardiac rhythms, heart failure and other cardiac and/or respiratory related conditions.
- Diaphragm stimulation has been used to provide breathing in patients unable to breath on their own. Diaphragm stimulation has also been proposed to treat sleep apnea. However, these uses of diaphragm stimulation have not provided optimal breathing responses or control of breathing.
- Breathing is typically intrinsically controlled by complex brain control and feedback sensing by the body.
- the body's involuntary control of respiration is mediated by the brain's respiratory center located in the brainstem, particularly in the medulla oblongata and pons.
- the respiratory center regulates the rhythmic alternating cycles of inspiration and expiration.
- the dorsal respiratory group within the medulla is responsible for the generation of respiratory rhythm through a reciprocal inhibition with other cell groups.
- central and peripheral receptors e.g., chemoreceptors and mechanoreceptors play important roles in regulation of inspiration.
- Central chemoreceptors of the central nervous system located on the ventrolateral medullary surface are sensitive to pH of their environment. It is believed that these chemoreceptors act to detect a change in pH of the cerebral spinal fluid.
- An increase in carbon dioxide tension of the arteries will indirectly cause the blood to become more acidic; the cerebral spinal fluid pH is closely comparable to plasma pH, as carbon dioxide easily diffuses across the blood/brain barrier.
- the detection of variation in the arterial carbon dioxide tension acts as a quick response system, useful in short term regulation. This system utilizes a negative feedback system, therefore if the pH of the cerebral spinal fluid is too low, then the receptor is believed in effect send an error signal to the medulla and respiration is adjusted accordingly.
- Peripheral chemoreceptors are believed most importantly to act to detect variation of the oxygen in the arterial blood, in addition to detecting arterial carbon dioxide and pH. These receptors are typically referred to as aortic or carotid bodies, and respectively are location on the arch of the aorta and on the arch of the common carotid artery.
- a continuous signal is sent, via cranial nerves from the peripheral chemoreceptors. With a decrease in arterial oxygen tension, the signal intensifies, calling for an increase in respiration. However, increase in respiration typically results in falling PCO2 and hydrogen ion concentration which creates strong respiratory inhibitory effects that oppose the excitatory effects of diminished oxygen.
- Mechanoreceptors are located for example, in the airways and parenchyma, and are responsible for a variety of reflex responses.
- Pulmonary Stretch Receptors are located in smooth muscles of the trachea down to the terminal bronchioles. They are innervated by large, myelinated fibers and they discharge in response to distension of the lung. Their vagally mediated inhibition of inspiration and promotion of expiration is believed to be sustained as long as the lung is distended. They contribute to what is known as the Hering-Breuer reflex which prevents over-inflation of the lungs, by providing feedback signals that cause termination of inspiration.
- receptors such as respiratory proprioreceptors located in muscle spindle endings and tendon organs of the respiratory muscles, are stimulated in response to rib movement or intercostals/diaphragmatic tendon force of contraction.
- respiration can be affected by conditions such as, e.g., emotional state via input from the limbic system, or temperature, via the hypothalamus.
- Voluntary control of the respiration is provided via the cerebral cortex, although chemoreceptor reflex is capable of overriding conscious control.
- the invention provides a device and method for electrically stimulating the diaphragm to control breathing while inhibiting respiratory drive.
- a stimulation phase is identified.
- the stimulation phase is a period of time within the breathing cycle in which stimulation will inhibit respiratory drive and most likely will occur during a first fraction of the rest phase.
- Baseline breathing is sensed and stored.
- the length of the rest period in a breathing cycle is identified and a stimulation phase is determined.
- the baseline is used to determine when to stimulate.
- EMG or other respiratory indicators may be sensed on a breath by breath basis or over time to determine when to stimulate within the respiratory phase.
- duration and respiratory rate may be varied to inhibit respiratory drive when stimulating.
- the respiratory drive inhibition may be used in a number of applications such as improving or remodeling the heart in heart failure patients, treating apnea, chronic obstructive pulmonary disorder (COPD), and hypertension.
- COPD chronic obstructive pulmonary disorder
- FIG. 1 is an exemplary respiratory waveform with an identified stimulation phase in accordance with the invention.
- FIG. 2 is a flow showing a baseline establishment in accordance with the invention.
- FIG. 3 is a flow chart showing identification of delivery boundaries in accordance with the invention.
- FIGS. 4A-4D illustrate various stimulation schemes in accordance with the invention, for controlling breathing in comparison to intrinsic breathing.
- FIG. 5 is a table illustrating a breathing therapy scheme in accordance with the invention.
- FIG. 6 is a flow chart showing a breathing therapy scheme in accordance with the invention.
- FIG. 7 illustrates an immediate control mode of a breathing therapy device in accordance with the invention.
- FIG. 8 illustrates a gradual control scheme in accordance with the invention.
- FIG. 9 is a flow chart showing an apnea control in accordance with the invention.
- FIG. 10 illustrates treatment of apnea in accordance with the invention.
- FIG. 11 illustrates a breathing therapy mode in accordance with the invention.
- FIG. 12 illustrates a diaphragm stimulator in accordance with the invention.
- a diaphragm stimulation device as shown in FIG. 12 is used.
- the diaphragm stimulation device 1200 electrically stimulates the diaphragm 1290 with an electrical signal supplied from a signal source 1260 to at least one electrode 1220 on an implantable unit 1210 .
- the electrode may also sense EMG of the diaphragm which may include respiration parameters.
- the sensed EMG is communicated to a processor 1280 of a control unit 1240 .
- the control unit also includes an input/output device 1250 for coupling to external communications device.
- the input/output device 1250 may be used to communicate to or from the device 1210 or the processor 1280 to or from a programmer, user or provider (e.g.
- the implantable unit 1210 also includes a motion sensor 1230 that senses the motion of the diaphragm 1290 to determine respiration parameters or responses to stimulation.
- the motion sensor 1230 may also be used to sense patient activity levels.
- the sensed signals are communicated to a processor 1280 that stores and uses the motion and EMG signals, as described herein, to control breathing.
- the phrenic nerve may be stimulated to control breathing.
- the waveform 100 has a total respiratory interval length 105 that comprises an inspiration period 110 , followed by an exhalation period 120 and ending in a rest period 130 .
- the respiratory interval 105 begins at the beginning 101 of the inspiration period 110 and ends at the end 160 of the rest period 130 which is the beginning of the next respiratory cycle.
- a time period is identified for stimulating a diaphragm and/or phrenic nerve to elicit a breathing response where the stimulation is believed to capture or take over breathing control and/or inhibit breathing driven by a subject's innate respiratory drive.
- the stimulation period 170 is identified by an earliest acceptable stimulation boundary 140 and a latest acceptable stimulation boundary 150 .
- the stimulation period 170 falls within the rest period 130 .
- the earliest stimulation boundary 140 may be selected on a patient by patient basis and is the earliest time at which the innate respiratory drive is captured by a particular stimulation.
- the stimulation boundary may be determined, e.g., on a patient by patient basis by optimizing stimulation response prior to implanting the device. Accordingly stimulation is provided and observed at different times near the beginning of the rest period to identify when the respiratory drive is captured for a particular stimulation waveform. In general, it is believed that such earliest stimulation boundary 140 is after the end of the exhalation period 120 and at or near the beginning of the rest cycle 130 .
- an earliest time may be selected for example as the end of the exhalation period 120 or a given time after the end of the exhalation cycle. It may also be selected as a predetermined fraction of the respiratory interval or its various components based on a baseline respiratory interval or interval component.
- the latest stimulation boundary 150 may be similarly selected on a patient by patient basis or using a predetermined value or a value based on a baseline.
- the latest stimulation boundary 150 is selected to occur at a time prior to the generation of an inspiration signal from the dorsal respiratory group.
- the latest stimulation boundary 150 is typically at time substantially before the expected onset of the next breath, i.e., before the end of the rest period.
- the latest stimulation boundary 150 is at about 0.9 of the total rest cycle length 130 .
- the latest stimulation boundary is a predetermined time prior to the end of the rest cycle 160 , more preferably at about 100 to 500 milliseconds prior to the end 160 of the rest cycle 130 .
- the identification of the inspiration cycle, exhalation cycle rest period, tidal volume and respiratory rate may be accomplished by sensing the respiration waveform, e.g., with a pneumotachometer, movement sensor or using EMG.
- An example of such determination is described, for example in related U.S. application Ser. No. 10/686,891 incorporated herein by reference.
- Various methods and devices that may be used to map ideal electrode placement for a desired result or to optimize stimulation to achieve such result are described in related U.S. Application entitled “SYSTEM AND METHOD FOR MAPPING DIAPHRAGM ELECTRODE SITES” filed on even date herewith and incorporated herein by reference.
- FIG. 2 is a flow chart illustrating a baseline determination in accordance with the invention.
- the device identifies the phase in which stimulation may be applied by sensing the respiratory phase length. This may be used during patient set up to establish patient baseline breathing.
- the baseline may be determined for several tidal volume levels or for one patient tidal volume, typically in a resting state. Baselines are established on a patient to patient basis because, e.g., each patient may have unique chest/lung compliance that could affect exhalation characteristics.
- a patient is connected to a flow sensor (e.g., a pneumotachometer).
- a flow sensor e.g., a pneumotachometer
- a patient is instructed to breathe at a resting respiratory rate and tidal volume.
- the respiration waveform is used as a baseline. From the respiration waveform, respiration parameters are measured, e.g., tidal volume, inspiration duration, exhalation duration, rest period, and respiratory rate. Thus the length of each segment of the inspiration cycle is determined for a given tidal volume.
- the minute ventilation may also be determined from the tidal volume and respiratory rate.
- step 230 which occurs with step 220 , the EMG is sensed and the EMG is correlated with the information sensed by the pneumotachometer in step 220 .
- the correlation is useful when the patient is no longer connected to the pneumotachometer. From the EMG and measured tidal volume the tidal volume for a subsequently observed EMG may be estimated or determined. At rest, exhalation is correlated to tidal volume. As tidal volume increases, so does the duration of exhalation. Thus, the exhalation phase for a given title volume can be generally determined as the exhalation phase is generally the same for a given tidal volume.
- step 240 diaphragm motion is sensed with a motion sensor. Diaphragm motion indicates when the lungs are inspiring, exhaling or at rest. This step is optional but provides additional correlation information.
- the motion sensor information is also correlated with EMG and pneumotachometer information.
- the respiration parameters are stored, i.e. the measured tidal volume and other sensed measured or calculated parameter, and correlated EMG, pneumotachometer and motion sensor data.
- steps 220 through 250 are repeated for a decreased tidal volume.
- a patient may be coached or instructed by a provider or programmer via telemetry to breathe at a lower tidal volume and the same measurements are then made as were made for a resting tidal volume.
- steps 220 through 250 are repeated for an increased tidal volume.
- a patient may be coached or instructed by a provider or programmer to breathe at a higher tidal volume and the same measurements are then made as were made for a resting tidal volume.
- the implanted device may be programmed accordingly and the device turned on.
- FIG. 3 illustrates the identification of phase boundaries when the device is in operation.
- the device senses EMG.
- step 320 the EMG is stored along with respiratory parameters that may be ascertained from EMG. This includes the inspiration period where EMG is active, the exhalation and rest period combined where EMG is inactive.
- step 340 the motion detector is used to differentiate between the exhalation phase in which there is diaphragm movement and the rest phase in which there is minimal diaphragm movement.
- the data points stored in step 230 of FIG. 2 are used to extrapolate the tidal volume for a given EMG.
- the exhalation period is generally known, thus the rest period may be determined by subtracting the exhalation period from the combined sensed exhalation and rest periods.
- the stimulation delivery boundaries are determined, i.e. the earliest stimulation boundary 140 and latest stimulation boundary 150 are determined.
- the stimulation may occur in the same cycle as the EMG or in a subsequent cycle assuming the previous cycle would be approximately the same.
- the earliest stimulation boundary is at a predetermined time after the end of the exhalation period.
- the latest stimulation boundary is a predetermined time before the end of the rest period.
- the earliest stimulation boundary is after a predetermined fraction of the expected rest cycle has passed.
- the latest stimulation boundary is before a predetermined fraction of the expected rest cycle has passed.
- Other ways of determining the stimulation phase may be used in accordance with the invention, including but not limited to using optimization as described above with reference to FIG. 1 .
- step 370 if treatment is desirable, then at step 380 , stimulation is provided during the stimulation phase as programmed. Subsequently, or if no treatment is required, the system resumes monitoring EMG.
- stimulation is provided that inhibits central respiratory drive for a sufficient duration so that therapeutic stimulation and breathing control may be applied.
- the therapeutic stimulation breathing is configured to provide a therapeutic benefit at the same time that it acts to inhibit central respiratory drive.
- the stimulation intensity, duration and respiratory rate are manipulated to inhibit respiratory drive while providing desired stimulation to the diaphragm. For example, at a given respiratory rate and tidal volume during diaphragm stimulation, extending the inspiration or expiration duration (among other things, by increasing stimulation duration and decreasing intensity) effectively shortens the resting period compared to spontaneous breathing and decreases the likelihood of a spontaneous breath between stimulations.
- One factor in inhibiting respiratory drive is to stimulate an inspiration between the rest phase boundaries and thereby activate the mechanoreceptors such as the stretch receptors and the proprioreceptors to provide feed back that an individual is actively inspiring.
- the stretch receptors activate when the airways/lungs stretch and the proprioreceptors activate when respiratory muscles of the diaphragm and/or chest wall contract.
- output from the respiratory center conducted by efferent nerves to the respiratory muscles are temporarily inhibited by the mechanoreceptor signals until the individual has exhaled.
- Another factor that affects respiratory drive is the blood oxygen concentration levels and the partial pressure of carbon dioxide in the blood.
- a decrease in carbon dioxide levels tends to create a decrease in respiratory drive whereas a decrease in oxygen saturation levels may increase respiratory drive.
- These levels and thus the chemoreceptors and respiratory drive may be influenced by controlling minute ventilation as is described in related U.S. Patent Application entitled “System and Method For Diaphragm Stimulation” filed on even date herewith and incorporated herein by reference. Accordingly, parameters that effect minute ventilation e.g., tidal volume and respiratory rate, may be manipulated to control respiratory drive.
- FIGS. 4A-4B and 4 D illustrate various stimulation schemes in accordance with the invention, for controlling breathing while maintaining central respiratory drive inhibition.
- FIG. 4C illustrates spontaneous breathing 450 with the dotted line showing what spontaneous breathing would continue to look like without stimulated breathing.
- stimulation is provided within the defined stimulation phase (See FIGS. 1 and 3 ) of the rest phase before the effect of the lack of mechanoreceptor activation allows the brain to initiate inspiration.
- tidal volume is maintained which is believed to help prevent other brain receptor functions from causing the initiation of inspiration.
- various stimulation responses may be tested until a desired response (e.g., tidal volume an respiratory rate) is obtained.
- a set of a series of stimulation pulses 410 , 411 , 412 is illustrated following a spontaneous breath 400 .
- Each of the series of pulses 410 , 411 , 412 elicit a slower rate and more shallow breathing (e.g., flow) response 420 , 421 , 422 in comparison to the spontaneous breaths 490 , 496 , 497 , 498 , while each maintaining a tidal volume approximately the same as the tidal volume of the spontaneous breaths 496 , 497 , 498 ( FIG. 4C ).
- Each of the initiation points 402 , 404 , 406 fall within a stimulation phase that is a less than or is a fraction of the spontaneous breath rest phase 495 ( FIG. 4C ).
- the rest phases 403 , 405 , 407 are shorter. Accordingly, spontaneous breathing is inhibited.
- FIG. 4B a set of a series of stimulation pulses 440 , 441 , 442 is illustrated following a spontaneous breath 430 .
- Each of the series of pulses 440 , 441 , 442 elicit a slower rate and more shallow breathing response 450 , 451 , 452 in comparison to the spontaneous breaths 490 , 496 , 497 , 498 , while each maintaining a tidal volume approximately the same as the tidal volume of the spontaneous breaths 496 , 497 , 498 ( FIG. 4C ).
- Each of the initiation points 432 , 434 , 436 fall within a stimulation phase that is a less than or is a fraction of the spontaneous breath rest phase 495 ( FIG. 4C ).
- the rest phases 433 , 435 , 437 are shorter than the rest phase 495 while somewhat longer than the rest phases 403 , 405 , and 407 of FIG. 4A . Accordingly, spontaneous breathing is inhibited.
- FIG. 4D illustrates a set of a series of stimulation pulses 470 , 471 , 472 is illustrated following a spontaneous breath 460 .
- Each of the series of pulses 470 , 471 , 472 elicit a similar breathing response 480 , 481 , 482 in comparison to the spontaneous breaths 490 , 496 , 497 , 498 ,(except the rate is faster) thus each maintaining a tidal volume approximately the same as the tidal volume of the spontaneous breaths 490 , 496 , 497 , 498 .
- Each of the initiation points 462 , 464 , 466 fall within a stimulation phase that is a less than or is a fraction of the spontaneous breath rest phase 495 ( FIG. 4C ). While the breathing responses 480 , 481 , 482 are similar or the same as those of the spontaneous breaths, 496 , 497 , 498 , the respiration rate is increased. Accordingly, spontaneous breathing is inhibited.
- the stimulation scheme of the invention may be used in a number of applications.
- a patient's breathing is captured by the stimulator and breathing stimulation is applied to control breathing for a period of time.
- breathing is stimulated to increase oxygen saturation levels for a period of time. It is believed that this scheme will allow positive remodeling of the heart by reducing the load on the heart for a period of time, e.g., for one or more time intervals during sleep. Reduced contractility and cardiac output for a period of time provides an opportunity for an overloaded heart to rest.
- the oxygen saturation levels can be increased by increasing minute ventilation. Therefore one aspect of the invention is a device and method for treating heart failure patients by providing breathing stimulation for periods of time that increase oxygen saturation levels.
- FIGS. 5-8 Examples of a breathing therapy schemes are shown in FIGS. 5-8 .
- tidal volume respiratory rate and minute ventilation are observed as described with respect to FIGS. 1-3 herein.
- Tidal volume is maintained at the normal level while respiratory rate is increased, thus increasing minute ventilation and SaO2 levels, decreasing PCO2 levels, and therefore maintaining central respiratory drive inhibition.
- This therapy mode is maintained for a programmable amount of time, e.g., for one or more intervals of time during the night or during the day.
- breathing therapy mode breathing is normalized to allow PCO2 to slowly increase so spontaneous breathing can be restored.
- FIG. 6 is a flow chart illustrating the scheme set forth in FIG. 5 .
- the breathing therapy scheme is activated, e.g. at a programmed time.
- control of breathing is taken over either immediately as described with respect to FIG. 7 , or gradually as described with respect to FIG. 8 .
- step 630 the stimulation delivery boundaries identified as described in FIG. 2 are recalled (which have been dynamically observed and recorded).
- the diaphragm is stimulated at an increased minute ventilation for a given or programmed duration.
- breathing stimulation is normalized and the normalization mode is activated. Stimulation at a normal minute ventilation is provided for a given duration or until spontaneous breathing returns.
- the weaning mode is activated and minute ventilation is decreased for a given duration or until spontaneous breathing returns.
- immediate control begins after a period of normal breathing 700 by taking over breathing at a point 705 within an identified stimulation phase. Stimulation of breathing at the increased respiratory rate is continuously applied for the breathing therapy portion 710 . Stimulation is then normalized for a period of normalization 720 and the patient is weaned for a period of weaning 730 . While not specifically shown in FIG. 7 , stimulation continues until the return of spontaneous breathing.
- FIG. 8 illustrates a gradual control mode.
- stimulated breaths 801 are induced between spontaneous breaths 800 .
- the effective minute ventilation is gradually increased as the rest period 812 between the spontaneous breath 800 and the subsequent stimulated breath 801 are shorter than the intrinsic rest period 811 .
- SaO2 will increase and PCO2 will decrease gradually decreasing the respiratory drive.
- the length of the rest period is determined, e.g., using a motion sensor, until it reaches a critical length that has increased due to decreased respiratory drive (e.g. at rest period 820 ending at 802 ).
- breathing is controlled by the stimulator as it has transitioned to the immediate control mode for a period of time 830 .
- breathing is normalized 840 and finally the patient is weaned 850 .
- Another aspect of the invention provides for breathing therapy in treating apnea. It is believed that stimulated breathing prior to or during apnea may stabilize the broad swings of blood gas concentrations that occur during cycles of Cheyne-Stokes and apnea. Further it is believed that diaphragmatic stimulation during apnea may stimulate vagal afferent signals to the respiratory center and thus may maintain vagal tone associated with restful sleeping. Vagal tone has a calming effect on heart rate, blood pressure and cardiac output during restful sleep stages. Furthermore, diaphragmatic stimulation may prevent a fall in oxygen saturation that would typically initiate an arousal episode during apnea. Arousal episodes are associated with increases of sympathetic nerve activity which increases ventilation rate, heart rate and blood pressure.
- the invention provides a device and method for preventing apnea arousals.
- the invention also provides a device and method for providing greater periods of restful sleep particularly in patients suffering from ongoing bouts of apnea and resulting arousal from sleep.
- apnea is detected and an episode is initiated.
- Apnea may be detected e.g., by a lack of EMG for a given period of time.
- stimulation is provided. If stimulation is provided during an apnea interval, (preferably at the beginning of the apnea level before SaO2 levels are depleted) stimulation is provided at a predetermined rate and tidal volume based on previous baseline determinations. In particular stimulation is provided at lower minute ventilation than normal. This is to gradually allow for more oxygenation than will occur during apnea while also allowing an increase in the PCO2 levels until the respiratory drive increases at least above the apneac threshold, and spontaneous breathing at a desired level returns. Cheyne-Stokes and apnea tend to occur in repeated cycles in heart failure patients.
- apnea therapy is to stabilize the blood gas levels more gradually and to reduce the extreme fluctuations between Cheyne-Stokes hyperventilation and apnea.
- the stimulation rate is set and may gradually be reduced by increasing the intervals between successive breaths or stimulations. If no EMG 940 is sensed within interval 930 or a sensed EMG does not meet the amplitude criterion and the interval length has not reached a maximum length, then the stimulation is delivered at step 920 and the cycle 930 & 940 repeated. If an EMG is sensed 940 within the 930 interval and meets amplitude criterion then the stimulation will be inhibited at step 950 . If a defined number of successive sensed EMGs meeting step 940 criterion are not met then the interval is again set at step 930 . If a defined number of successive sensed EMGs meeting step 940 criterion are met in step 960 then the episode is over and the device returns to apnea detection mode 910 .
- FIG. 10 illustrates apnea treatment as described with respect to FIG. 9 .
- the waveform at 1000 may be a normal intrinsic breath.
- a breath with an increased amplitude may be a precursor to Cheyne-Stokes hyperventilation that may indicate the imminent onset of Cheyne-Stokes.
- Cheyne-Stokes hyperventilation is at a peak amplitude.
- the amplitude is decreasing indication the imminent onset of apnea.
- apnea has occurred.
- a precursor to apnea may be sensed and stimulation may be provided to take over breathing in a manner similar to that described with reference to FIGS. 5-8 .
- the stimulation may be adjusted to increase or decrease minute ventilation to stabilize blood gas fluctuations and avoid further episodes of Cheyne-Stokes and/or apnea. Maintaining stable blood gas levels with stimulation may prevent Cheyne-Stokes hyperventilation and hence avoid arousal events otherwise associated with large swings of these gases.
- stimulation begins at 1050 .
- stimulation is at minute ventilation that is reduced from a normal baseline.
- the intervals between stimulation cycles increase.
- an EMG is sensed but it is not at a desired level and the stimulation continues.
- an EMG is sensed and stimulation is inhibited until an interval passes.
- a set interval has passed without spontaneous breathing and stimulation then resumes.
- spontaneous breathing has resumed and continues for a requisite number of cycles (until point 1099 is reached). It is then determined that the episode is over and the system returns to apnea sensing mode.
- precursors to apnea or to Cheyne-Stokes may be sensed and treated.
- a precursor to apnea may be detected in a number of ways, for example, by detecting Cheyne-Stokes hyperventilation or a precursor to Cheyne-Stokes hyperventilation.
- a precursor to apnea may be detected by detecting periodic breathing throughout a day prior to night time. If this is the case stimulation is delivered throughout the night, in intervals as described with respect to FIGS. 5-8 .
- the device may be set to detect actual apnea events if they occur in spite of administering breathing therapy as described with respect to FIGS.
- FIGS. 11A-B illustrate an example of a hypertension breathing therapy device.
- capture of breathing as described in FIGS. 5-8 may occur on a nightly basis for specific preprogrammed durations.
- stimulation may also be provided during an exhalation cycle to further extend the length of the active breathing portion (inspiration and exhalation) of the respiration cycle.
- the duration of the rest period is greatly reduced so that the central respiratory drive may remain inhibited.
- the minute ventilation is maintained in accordance with a baseline determined as described with reference to FIG. 2 .
- the goal is to create long slow breathing, e.g., at about 6 cycles per minute or at another rate that provides desired therapy.
- FIGS. 11A-B illustrates an example of inducing slow controlled breathing therapy.
- FIG. 11A illustrates the breathing morphology while FIG. 11B illustrates the corresponding stimulation bursts or series of pulses.
- spontaneous breathing is occurring which can be used as a baseline.
- breathing is captured and the breathing rate is slowed.
- stimulation induces an inspiration cycle with a passive exhalation and a rest period as in spontaneous breathing.
- period 1120 stimulation ramps up to induce an inspiration cycle, as in period 1110 , and gradually ramps down during exhalation to extend the length of the exhalation cycle.
- the normally passive exhalation phase is now influenced with active stimulation.
- the increase in the duration of the active breathing portion of the respiration cycle decreases the rest phase duration which tends to inhibit the occurrence of spontaneous breathing.
- minute ventilation is approximately equal to minute ventilation during period 1110 which is achieved by increasing the tidal volume and decreasing the rate.
- the stimulation 1131 becomes longer in duration than stimulation 1130 , further extending the duration of the breaths and decreasing the rest phase, which inhibits spontaneous breathing and maintains a decreased respiration rate.
- the stimulation 1132 decreases in duration and stimulation is inhibited.
- the stimulation is turned off or stimulation is gradually returned to normal breathing in a manner similar to that described in examples above. Spontaneous breathing will then resume.
- the breathing rate is reduced to 20 breaths per minute or less, more preferably about 10 breaths per minute or less and most preferably between about 4 and 8 breaths per minute.
- the respiratory drive inhibition may also be used in treating COPD patients.
- COPD patients have difficulties exhaling CO 2 and therefore typically retain high levels of CO 2 in their blood.
- Low levels of inspiration with high levels of exhalation may be induced by inducing longer periods of exhalation in a manner similar to that described with respect to FIGS. 11A-11B where the exhalation period is extended.
Abstract
A device and method is provided for electrically stimulating the diaphragm to control breathing while inhibiting respiratory drive. A stimulation phase is identified. The stimulation phase is a period of time within the breathing cycle in which stimulation will inhibit respiratory drive. The respiratory drive inhibition may be used in a number of applications including but not limited to: improving or remodeling the heart in heart failure patients, treating apnea, chronic obstructive pulmonary disorder (COPD), and hypertension.
Description
- This application is a continuation-in-part of U.S. application Ser. No. 10/686,891 filed Oct. 15, 2003, fully incorporated herein by reference.
- The invention relates to a device and method for detection, diagnosis and treatment of breathing disorders and to the management of pulmonary or cardiac rhythms, heart failure and other cardiac and/or respiratory related conditions.
- Diaphragm stimulation has been used to provide breathing in patients unable to breath on their own. Diaphragm stimulation has also been proposed to treat sleep apnea. However, these uses of diaphragm stimulation have not provided optimal breathing responses or control of breathing.
- Accordingly it would be desirable to provide improved diaphragm stimulation.
- Breathing is typically intrinsically controlled by complex brain control and feedback sensing by the body. The body's involuntary control of respiration is mediated by the brain's respiratory center located in the brainstem, particularly in the medulla oblongata and pons. The respiratory center regulates the rhythmic alternating cycles of inspiration and expiration. The dorsal respiratory group within the medulla is responsible for the generation of respiratory rhythm through a reciprocal inhibition with other cell groups.
- In addition, various central and peripheral receptors, e.g., chemoreceptors and mechanoreceptors play important roles in regulation of inspiration.
- Central chemoreceptors of the central nervous system located on the ventrolateral medullary surface, are sensitive to pH of their environment. It is believed that these chemoreceptors act to detect a change in pH of the cerebral spinal fluid. An increase in carbon dioxide tension of the arteries will indirectly cause the blood to become more acidic; the cerebral spinal fluid pH is closely comparable to plasma pH, as carbon dioxide easily diffuses across the blood/brain barrier. The detection of variation in the arterial carbon dioxide tension acts as a quick response system, useful in short term regulation. This system utilizes a negative feedback system, therefore if the pH of the cerebral spinal fluid is too low, then the receptor is believed in effect send an error signal to the medulla and respiration is adjusted accordingly.
- Peripheral chemoreceptors are believed most importantly to act to detect variation of the oxygen in the arterial blood, in addition to detecting arterial carbon dioxide and pH. These receptors are typically referred to as aortic or carotid bodies, and respectively are location on the arch of the aorta and on the arch of the common carotid artery. A continuous signal is sent, via cranial nerves from the peripheral chemoreceptors. With a decrease in arterial oxygen tension, the signal intensifies, calling for an increase in respiration. However, increase in respiration typically results in falling PCO2 and hydrogen ion concentration which creates strong respiratory inhibitory effects that oppose the excitatory effects of diminished oxygen.
- Mechanoreceptors are located for example, in the airways and parenchyma, and are responsible for a variety of reflex responses.
- Pulmonary Stretch Receptors are located in smooth muscles of the trachea down to the terminal bronchioles. They are innervated by large, myelinated fibers and they discharge in response to distension of the lung. Their vagally mediated inhibition of inspiration and promotion of expiration is believed to be sustained as long as the lung is distended. They contribute to what is known as the Hering-Breuer reflex which prevents over-inflation of the lungs, by providing feedback signals that cause termination of inspiration.
- Other receptors, such as respiratory proprioreceptors located in muscle spindle endings and tendon organs of the respiratory muscles, are stimulated in response to rib movement or intercostals/diaphragmatic tendon force of contraction.
- In addition to involuntary control of respiration by the respiratory center, respiration can be affected by conditions such as, e.g., emotional state via input from the limbic system, or temperature, via the hypothalamus. Voluntary control of the respiration is provided via the cerebral cortex, although chemoreceptor reflex is capable of overriding conscious control.
- Known diaphragm stimulation techniques have not interacted with this complex respiratory control system to override, influence or work with the system.
- Accordingly improved stimulation devices and methods would be desirable.
- The invention provides a device and method for electrically stimulating the diaphragm to control breathing while inhibiting respiratory drive. According to the invention, a stimulation phase is identified. The stimulation phase is a period of time within the breathing cycle in which stimulation will inhibit respiratory drive and most likely will occur during a first fraction of the rest phase. Baseline breathing is sensed and stored. The length of the rest period in a breathing cycle is identified and a stimulation phase is determined.
- The baseline is used to determine when to stimulate. EMG or other respiratory indicators may be sensed on a breath by breath basis or over time to determine when to stimulate within the respiratory phase. For a given tidal volume stimulation amplitude, duration and respiratory rate may be varied to inhibit respiratory drive when stimulating.
- The respiratory drive inhibition may be used in a number of applications such as improving or remodeling the heart in heart failure patients, treating apnea, chronic obstructive pulmonary disorder (COPD), and hypertension.
-
FIG. 1 is an exemplary respiratory waveform with an identified stimulation phase in accordance with the invention. -
FIG. 2 is a flow showing a baseline establishment in accordance with the invention. -
FIG. 3 is a flow chart showing identification of delivery boundaries in accordance with the invention. -
FIGS. 4A-4D illustrate various stimulation schemes in accordance with the invention, for controlling breathing in comparison to intrinsic breathing. -
FIG. 5 is a table illustrating a breathing therapy scheme in accordance with the invention. -
FIG. 6 is a flow chart showing a breathing therapy scheme in accordance with the invention. -
FIG. 7 illustrates an immediate control mode of a breathing therapy device in accordance with the invention. -
FIG. 8 illustrates a gradual control scheme in accordance with the invention. -
FIG. 9 is a flow chart showing an apnea control in accordance with the invention. -
FIG. 10 illustrates treatment of apnea in accordance with the invention. -
FIG. 11 illustrates a breathing therapy mode in accordance with the invention. -
FIG. 12 illustrates a diaphragm stimulator in accordance with the invention. - In accordance with the invention a diaphragm stimulation device as shown in
FIG. 12 is used. Thediaphragm stimulation device 1200 electrically stimulates thediaphragm 1290 with an electrical signal supplied from asignal source 1260 to at least oneelectrode 1220 on animplantable unit 1210. The electrode may also sense EMG of the diaphragm which may include respiration parameters. The sensed EMG is communicated to aprocessor 1280 of acontrol unit 1240. The control unit also includes an input/output device 1250 for coupling to external communications device. The input/output device 1250 may be used to communicate to or from thedevice 1210 or theprocessor 1280 to or from a programmer, user or provider (e.g. via telemetry, wireless communications or other user/provider/programmer interface). Theimplantable unit 1210 also includes amotion sensor 1230 that senses the motion of thediaphragm 1290 to determine respiration parameters or responses to stimulation. Themotion sensor 1230 may also be used to sense patient activity levels. The sensed signals are communicated to aprocessor 1280 that stores and uses the motion and EMG signals, as described herein, to control breathing. In addition to stimulation of the diaphragm the phrenic nerve may be stimulated to control breathing. - Referring to
FIG. 1 anintrinsic breathing waveform 100 is illustrated. Thewaveform 100 has a totalrespiratory interval length 105 that comprises aninspiration period 110, followed by an exhalation period 120 and ending in arest period 130. Therespiratory interval 105 begins at the beginning 101 of theinspiration period 110 and ends at theend 160 of therest period 130 which is the beginning of the next respiratory cycle. In accordance with the invention as described below a time period is identified for stimulating a diaphragm and/or phrenic nerve to elicit a breathing response where the stimulation is believed to capture or take over breathing control and/or inhibit breathing driven by a subject's innate respiratory drive. Thestimulation period 170 is identified by an earliestacceptable stimulation boundary 140 and a latestacceptable stimulation boundary 150. - In general the
stimulation period 170 falls within therest period 130. Theearliest stimulation boundary 140 may be selected on a patient by patient basis and is the earliest time at which the innate respiratory drive is captured by a particular stimulation. The stimulation boundary may be determined, e.g., on a patient by patient basis by optimizing stimulation response prior to implanting the device. Accordingly stimulation is provided and observed at different times near the beginning of the rest period to identify when the respiratory drive is captured for a particular stimulation waveform. In general, it is believed that suchearliest stimulation boundary 140 is after the end of the exhalation period 120 and at or near the beginning of therest cycle 130. As an alternative to optimizing on a patient by patient basis an earliest time may be selected for example as the end of the exhalation period 120 or a given time after the end of the exhalation cycle. It may also be selected as a predetermined fraction of the respiratory interval or its various components based on a baseline respiratory interval or interval component. - The
latest stimulation boundary 150 may be similarly selected on a patient by patient basis or using a predetermined value or a value based on a baseline. In general, in order to capture respiration with stimulation for a subject's given minute ventilation, according to one embodiment, thelatest stimulation boundary 150 is selected to occur at a time prior to the generation of an inspiration signal from the dorsal respiratory group. Accordingly, thelatest stimulation boundary 150 is typically at time substantially before the expected onset of the next breath, i.e., before the end of the rest period. In particular, according to one variation, thelatest stimulation boundary 150 is at about 0.9 of the totalrest cycle length 130. According to another variation, the latest stimulation boundary is a predetermined time prior to the end of therest cycle 160, more preferably at about 100 to 500 milliseconds prior to theend 160 of therest cycle 130. - The identification of the inspiration cycle, exhalation cycle rest period, tidal volume and respiratory rate may be accomplished by sensing the respiration waveform, e.g., with a pneumotachometer, movement sensor or using EMG. An example of such determination is described, for example in related U.S. application Ser. No. 10/686,891 incorporated herein by reference. Various methods and devices that may be used to map ideal electrode placement for a desired result or to optimize stimulation to achieve such result are described in related U.S. Application entitled “SYSTEM AND METHOD FOR MAPPING DIAPHRAGM ELECTRODE SITES” filed on even date herewith and incorporated herein by reference.
-
FIG. 2 is a flow chart illustrating a baseline determination in accordance with the invention. The device identifies the phase in which stimulation may be applied by sensing the respiratory phase length. This may be used during patient set up to establish patient baseline breathing. The baseline may be determined for several tidal volume levels or for one patient tidal volume, typically in a resting state. Baselines are established on a patient to patient basis because, e.g., each patient may have unique chest/lung compliance that could affect exhalation characteristics. - In
step 210, a patient is connected to a flow sensor (e.g., a pneumotachometer). - In step 220 a patient is instructed to breathe at a resting respiratory rate and tidal volume. The respiration waveform is used as a baseline. From the respiration waveform, respiration parameters are measured, e.g., tidal volume, inspiration duration, exhalation duration, rest period, and respiratory rate. Thus the length of each segment of the inspiration cycle is determined for a given tidal volume. The minute ventilation may also be determined from the tidal volume and respiratory rate.
- At
step 230 which occurs withstep 220, the EMG is sensed and the EMG is correlated with the information sensed by the pneumotachometer instep 220. The correlation is useful when the patient is no longer connected to the pneumotachometer. From the EMG and measured tidal volume the tidal volume for a subsequently observed EMG may be estimated or determined. At rest, exhalation is correlated to tidal volume. As tidal volume increases, so does the duration of exhalation. Thus, the exhalation phase for a given title volume can be generally determined as the exhalation phase is generally the same for a given tidal volume. - In
step 240 which occurs withsteps - At
step 250 the respiration parameters are stored, i.e. the measured tidal volume and other sensed measured or calculated parameter, and correlated EMG, pneumotachometer and motion sensor data. - At
step 260,steps 220 through 250 are repeated for a decreased tidal volume. A patient may be coached or instructed by a provider or programmer via telemetry to breathe at a lower tidal volume and the same measurements are then made as were made for a resting tidal volume. - At
step 270,steps 220 through 250 are repeated for an increased tidal volume. A patient may be coached or instructed by a provider or programmer to breathe at a higher tidal volume and the same measurements are then made as were made for a resting tidal volume. - Once the initial baseline data and waveforms are stored, the implanted device may be programmed accordingly and the device turned on.
-
FIG. 3 illustrates the identification of phase boundaries when the device is in operation. - As illustrated in
step 310, the device senses EMG. - In
step 320 the EMG is stored along with respiratory parameters that may be ascertained from EMG. This includes the inspiration period where EMG is active, the exhalation and rest period combined where EMG is inactive. - At
step 330 if a motion sensor is in use on the diaphragm, then atstep 340 the motion detector is used to differentiate between the exhalation phase in which there is diaphragm movement and the rest phase in which there is minimal diaphragm movement. - At
step 330, if the motion sensor is not in use on the diaphragm, then atstep 350, the data points stored instep 230 ofFIG. 2 are used to extrapolate the tidal volume for a given EMG. For a given tidal volume, the exhalation period is generally known, thus the rest period may be determined by subtracting the exhalation period from the combined sensed exhalation and rest periods. - At
step 360, following either step 340 or step 350, the stimulation delivery boundaries are determined, i.e. theearliest stimulation boundary 140 andlatest stimulation boundary 150 are determined. The stimulation may occur in the same cycle as the EMG or in a subsequent cycle assuming the previous cycle would be approximately the same. In one example, the earliest stimulation boundary is at a predetermined time after the end of the exhalation period. The latest stimulation boundary is a predetermined time before the end of the rest period. In another example the earliest stimulation boundary is after a predetermined fraction of the expected rest cycle has passed. And, the latest stimulation boundary is before a predetermined fraction of the expected rest cycle has passed. Other ways of determining the stimulation phase may be used in accordance with the invention, including but not limited to using optimization as described above with reference toFIG. 1 . - At
step 370, if treatment is desirable, then atstep 380, stimulation is provided during the stimulation phase as programmed. Subsequently, or if no treatment is required, the system resumes monitoring EMG. - According to one aspect of the invention, stimulation is provided that inhibits central respiratory drive for a sufficient duration so that therapeutic stimulation and breathing control may be applied. The therapeutic stimulation breathing is configured to provide a therapeutic benefit at the same time that it acts to inhibit central respiratory drive. According to one aspect the stimulation intensity, duration and respiratory rate are manipulated to inhibit respiratory drive while providing desired stimulation to the diaphragm. For example, at a given respiratory rate and tidal volume during diaphragm stimulation, extending the inspiration or expiration duration (among other things, by increasing stimulation duration and decreasing intensity) effectively shortens the resting period compared to spontaneous breathing and decreases the likelihood of a spontaneous breath between stimulations.
- One factor in inhibiting respiratory drive is to stimulate an inspiration between the rest phase boundaries and thereby activate the mechanoreceptors such as the stretch receptors and the proprioreceptors to provide feed back that an individual is actively inspiring. The stretch receptors activate when the airways/lungs stretch and the proprioreceptors activate when respiratory muscles of the diaphragm and/or chest wall contract. Typically output from the respiratory center conducted by efferent nerves to the respiratory muscles are temporarily inhibited by the mechanoreceptor signals until the individual has exhaled.
- Another factor that affects respiratory drive is the blood oxygen concentration levels and the partial pressure of carbon dioxide in the blood. A decrease in carbon dioxide levels tends to create a decrease in respiratory drive whereas a decrease in oxygen saturation levels may increase respiratory drive. These levels and thus the chemoreceptors and respiratory drive may be influenced by controlling minute ventilation as is described in related U.S. Patent Application entitled “System and Method For Diaphragm Stimulation” filed on even date herewith and incorporated herein by reference. Accordingly, parameters that effect minute ventilation e.g., tidal volume and respiratory rate, may be manipulated to control respiratory drive.
-
FIGS. 4A-4B and 4D illustrate various stimulation schemes in accordance with the invention, for controlling breathing while maintaining central respiratory drive inhibition.FIG. 4C illustratesspontaneous breathing 450 with the dotted line showing what spontaneous breathing would continue to look like without stimulated breathing. - According to one aspect stimulation is provided within the defined stimulation phase (See
FIGS. 1 and 3 ) of the rest phase before the effect of the lack of mechanoreceptor activation allows the brain to initiate inspiration. In addition, tidal volume is maintained which is believed to help prevent other brain receptor functions from causing the initiation of inspiration. - As noted previously, in setting up and programming the device for a specific patient, various stimulation responses may be tested until a desired response (e.g., tidal volume an respiratory rate) is obtained.
- Referring to
FIG. 4A a set of a series ofstimulation pulses spontaneous breath 400. Each of the series ofpulses response spontaneous breaths spontaneous breaths FIG. 4C ). Each of the initiation points 402, 404, 406 fall within a stimulation phase that is a less than or is a fraction of the spontaneous breath rest phase 495 (FIG. 4C ). The rest phases 403, 405, 407 are shorter. Accordingly, spontaneous breathing is inhibited. - Similarly in
FIG. 4B a set of a series ofstimulation pulses spontaneous breath 430. Each of the series ofpulses shallow breathing response spontaneous breaths spontaneous breaths FIG. 4C ). Each of the initiation points 432, 434, 436 fall within a stimulation phase that is a less than or is a fraction of the spontaneous breath rest phase 495 (FIG. 4C ). The rest phases 433, 435, 437 are shorter than therest phase 495 while somewhat longer than the rest phases 403, 405, and 407 ofFIG. 4A . Accordingly, spontaneous breathing is inhibited. -
FIG. 4D illustrates a set of a series ofstimulation pulses spontaneous breath 460. Each of the series ofpulses similar breathing response spontaneous breaths spontaneous breaths FIG. 4C ). While thebreathing responses - The stimulation scheme of the invention may be used in a number of applications. In general, a patient's breathing is captured by the stimulator and breathing stimulation is applied to control breathing for a period of time.
- In one application, breathing is stimulated to increase oxygen saturation levels for a period of time. It is believed that this scheme will allow positive remodeling of the heart by reducing the load on the heart for a period of time, e.g., for one or more time intervals during sleep. Reduced contractility and cardiac output for a period of time provides an opportunity for an overloaded heart to rest. The oxygen saturation levels can be increased by increasing minute ventilation. Therefore one aspect of the invention is a device and method for treating heart failure patients by providing breathing stimulation for periods of time that increase oxygen saturation levels.
- Examples of a breathing therapy schemes are shown in
FIGS. 5-8 . As shown inFIG. 5 , during normal breathing tidal volume respiratory rate and minute ventilation are observed as described with respect toFIGS. 1-3 herein. Tidal volume is maintained at the normal level while respiratory rate is increased, thus increasing minute ventilation and SaO2 levels, decreasing PCO2 levels, and therefore maintaining central respiratory drive inhibition. This therapy mode is maintained for a programmable amount of time, e.g., for one or more intervals of time during the night or during the day. After the breathing therapy mode, breathing is normalized to allow PCO2 to slowly increase so spontaneous breathing can be restored. This may be accomplished by returning respiratory rate back to normal and maintaining normal tidal volume to increase PCO2 and thereby encourage the return of intrinsic breathing and respiratory drive. If after the stimulator stimulates breathing at a normal rate for a period of time and spontaneous breathing has not returned, the patient is weaned from the stimulator by further decreasing the respiratory rate and therefore minute ventilation. This will allow intrinsic breathing and respiratory drive to return by allowing an increase in PCO2. -
FIG. 6 is a flow chart illustrating the scheme set forth inFIG. 5 . Atstep 610 the breathing therapy scheme is activated, e.g. at a programmed time. - At
step 620, control of breathing is taken over either immediately as described with respect toFIG. 7 , or gradually as described with respect toFIG. 8 . - At
step 630 the stimulation delivery boundaries identified as described inFIG. 2 are recalled (which have been dynamically observed and recorded). - At
step 640 the diaphragm is stimulated at an increased minute ventilation for a given or programmed duration. - At
step 650 breathing stimulation is normalized and the normalization mode is activated. Stimulation at a normal minute ventilation is provided for a given duration or until spontaneous breathing returns. - At
step 660, the weaning mode is activated and minute ventilation is decreased for a given duration or until spontaneous breathing returns. - Referring to
FIG. 7 , immediate control begins after a period ofnormal breathing 700 by taking over breathing at apoint 705 within an identified stimulation phase. Stimulation of breathing at the increased respiratory rate is continuously applied for thebreathing therapy portion 710. Stimulation is then normalized for a period ofnormalization 720 and the patient is weaned for a period of weaning 730. While not specifically shown inFIG. 7 , stimulation continues until the return of spontaneous breathing. -
FIG. 8 illustrates a gradual control mode. In thefirst portion 810 of the gradual control mode stimulatedbreaths 801 are induced betweenspontaneous breaths 800. The effective minute ventilation is gradually increased as therest period 812 between thespontaneous breath 800 and the subsequent stimulatedbreath 801 are shorter than theintrinsic rest period 811. Over time in thisfirst portion 810 of the gradual mode, SaO2 will increase and PCO2 will decrease gradually decreasing the respiratory drive. The length of the rest period is determined, e.g., using a motion sensor, until it reaches a critical length that has increased due to decreased respiratory drive (e.g. atrest period 820 ending at 802). At that point breathing is controlled by the stimulator as it has transitioned to the immediate control mode for a period oftime 830. Then breathing is normalized 840 and finally the patient is weaned 850. - Another aspect of the invention provides for breathing therapy in treating apnea. It is believed that stimulated breathing prior to or during apnea may stabilize the broad swings of blood gas concentrations that occur during cycles of Cheyne-Stokes and apnea. Further it is believed that diaphragmatic stimulation during apnea may stimulate vagal afferent signals to the respiratory center and thus may maintain vagal tone associated with restful sleeping. Vagal tone has a calming effect on heart rate, blood pressure and cardiac output during restful sleep stages. Furthermore, diaphragmatic stimulation may prevent a fall in oxygen saturation that would typically initiate an arousal episode during apnea. Arousal episodes are associated with increases of sympathetic nerve activity which increases ventilation rate, heart rate and blood pressure. If oxygen saturation falls below a threshold, it is believed that hyperventilation will attempt to compensate for the falling oxygen saturation and also create arousal. Accordingly the invention provides a device and method for preventing apnea arousals. The invention also provides a device and method for providing greater periods of restful sleep particularly in patients suffering from ongoing bouts of apnea and resulting arousal from sleep.
- Referring to
FIG. 9 atstep 910 apnea is detected and an episode is initiated. Apnea may be detected e.g., by a lack of EMG for a given period of time. - At
step 920, stimulation is provided. If stimulation is provided during an apnea interval, (preferably at the beginning of the apnea level before SaO2 levels are depleted) stimulation is provided at a predetermined rate and tidal volume based on previous baseline determinations. In particular stimulation is provided at lower minute ventilation than normal. This is to gradually allow for more oxygenation than will occur during apnea while also allowing an increase in the PCO2 levels until the respiratory drive increases at least above the apneac threshold, and spontaneous breathing at a desired level returns. Cheyne-Stokes and apnea tend to occur in repeated cycles in heart failure patients. This is believed to occur in part due to the delay in the feedback or chemoreceptor sensing due to circulatory delay which is common in heart failure patients. The purpose of the apnea therapy described herein is to stabilize the blood gas levels more gradually and to reduce the extreme fluctuations between Cheyne-Stokes hyperventilation and apnea. - At
step 930, the stimulation rate is set and may gradually be reduced by increasing the intervals between successive breaths or stimulations. If noEMG 940 is sensed withininterval 930 or a sensed EMG does not meet the amplitude criterion and the interval length has not reached a maximum length, then the stimulation is delivered atstep 920 and thecycle 930 & 940 repeated. If an EMG is sensed 940 within the 930 interval and meets amplitude criterion then the stimulation will be inhibited atstep 950. If a defined number of successive sensedEMGs meeting step 940 criterion are not met then the interval is again set atstep 930. If a defined number of successive sensedEMGs meeting step 940 criterion are met instep 960 then the episode is over and the device returns toapnea detection mode 910. -
FIG. 10 illustrates apnea treatment as described with respect toFIG. 9 . The waveform at 1000 may be a normal intrinsic breath. At 1010 a breath with an increased amplitude may be a precursor to Cheyne-Stokes hyperventilation that may indicate the imminent onset of Cheyne-Stokes. At 1020 Cheyne-Stokes hyperventilation is at a peak amplitude. At 1030 the amplitude is decreasing indication the imminent onset of apnea. At 1040, apnea has occurred. At 1010, 1020, or 1030, a precursor to apnea may be sensed and stimulation may be provided to take over breathing in a manner similar to that described with reference toFIGS. 5-8 . The stimulation may be adjusted to increase or decrease minute ventilation to stabilize blood gas fluctuations and avoid further episodes of Cheyne-Stokes and/or apnea. Maintaining stable blood gas levels with stimulation may prevent Cheyne-Stokes hyperventilation and hence avoid arousal events otherwise associated with large swings of these gases. - If detection of apnea occurs, e.g., at
point 1040, then stimulation begins at 1050. As described with respect toFIG. 9 , stimulation is at minute ventilation that is reduced from a normal baseline. At 1060 the intervals between stimulation cycles increase. At 1070 an EMG is sensed but it is not at a desired level and the stimulation continues. At 1080 an EMG is sensed and stimulation is inhibited until an interval passes. At 1090 a set interval has passed without spontaneous breathing and stimulation then resumes. At 1095 spontaneous breathing has resumed and continues for a requisite number of cycles (until point 1099 is reached). It is then determined that the episode is over and the system returns to apnea sensing mode. - As an alternative to detecting apnea as an episode is occurring, precursors to apnea or to Cheyne-Stokes may be sensed and treated. A precursor to apnea may be detected in a number of ways, for example, by detecting Cheyne-Stokes hyperventilation or a precursor to Cheyne-Stokes hyperventilation. Also a precursor to apnea may be detected by detecting periodic breathing throughout a day prior to night time. If this is the case stimulation is delivered throughout the night, in intervals as described with respect to
FIGS. 5-8 . In addition, the device may be set to detect actual apnea events if they occur in spite of administering breathing therapy as described with respect toFIGS. 9 and 10 herein. Detection of precursors is described in more detail in related U.S. Application entitled: “BREATHING DISORDER AND PRECURSOR PREDICTOR AND THERAPY DELIVERY DEVICE AND METHOD” filed on even date herewith and incorporated herein by reference. - In accordance with another aspect of the invention, provides for treatment of hypertension. Studies have shown that patients coached to breath at about 6 breaths per minute have a reduction in blood pressure and resting oxygen saturation is improved.
-
FIGS. 11A-B illustrate an example of a hypertension breathing therapy device. According to the example, capture of breathing as described inFIGS. 5-8 may occur on a nightly basis for specific preprogrammed durations. In addition stimulation may also be provided during an exhalation cycle to further extend the length of the active breathing portion (inspiration and exhalation) of the respiration cycle. The duration of the rest period is greatly reduced so that the central respiratory drive may remain inhibited. The minute ventilation is maintained in accordance with a baseline determined as described with reference toFIG. 2 . The goal is to create long slow breathing, e.g., at about 6 cycles per minute or at another rate that provides desired therapy. -
FIGS. 11A-B illustrates an example of inducing slow controlled breathing therapy.FIG. 11A illustrates the breathing morphology whileFIG. 11B illustrates the corresponding stimulation bursts or series of pulses. During thefirst period 1100 spontaneous breathing is occurring which can be used as a baseline. During asecond period 1110, breathing is captured and the breathing rate is slowed. Duringperiod 1110, stimulation induces an inspiration cycle with a passive exhalation and a rest period as in spontaneous breathing. - Subsequently during
period 1120 stimulation ramps up to induce an inspiration cycle, as inperiod 1110, and gradually ramps down during exhalation to extend the length of the exhalation cycle. Thus, the normally passive exhalation phase is now influenced with active stimulation. The increase in the duration of the active breathing portion of the respiration cycle decreases the rest phase duration which tends to inhibit the occurrence of spontaneous breathing. Duringperiod 1120 minute ventilation is approximately equal to minute ventilation duringperiod 1110 which is achieved by increasing the tidal volume and decreasing the rate. In the period 1120(the therapy cycle), thestimulation 1131 becomes longer in duration thanstimulation 1130, further extending the duration of the breaths and decreasing the rest phase, which inhibits spontaneous breathing and maintains a decreased respiration rate. Then thestimulation 1132 decreases in duration and stimulation is inhibited. After breathing therapy is complete, the stimulation is turned off or stimulation is gradually returned to normal breathing in a manner similar to that described in examples above. Spontaneous breathing will then resume. In accordance with this aspect of the invention preferably the breathing rate is reduced to 20 breaths per minute or less, more preferably about 10 breaths per minute or less and most preferably between about 4 and 8 breaths per minute. - The respiratory drive inhibition may also be used in treating COPD patients. COPD patients have difficulties exhaling CO2 and therefore typically retain high levels of CO2 in their blood. Low levels of inspiration with high levels of exhalation may be induced by inducing longer periods of exhalation in a manner similar to that described with respect to
FIGS. 11A-11B where the exhalation period is extended. - While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention.
Claims (40)
1-43. (canceled)
44. A method of controlling breathing comprising the steps of:
electrically stimulating a patient to activate diaphragm activation to elicit breathing at a first rate greater than an intrinsic rate; and
subsequently electrically stimulating a patient to activate diaphragm activation to elicit breathing at a second rate greater than less than the first rate.
45. The method of controlling breathing of claim 44 wherein the step of electrically stimulating at a second rate comprises stimulating at a rate approximately at a normal intrinsic rate.
46. The method of controlling breathing of claim 44 further comprising the step of weaning the patient from the stimulation.
47. A device for controlling breathing comprising:
an electrical stimulator programmed to activate a diaphragm to elicit breathing at a first rate greater than an intrinsic rate; and
subsequently to activate diaphragm to elicit breathing at a second rate greater than less than the first rate.
48. The device of claim 47 wherein the stimulator is programmed to electrically stimulate at the second rate wherein the second rate is approximately at a normal intrinsic rate.
49. The device of claim 47 wherein the stimulator is further programmed to weaning the patient from the stimulation.
50. A method of treating breathing disorders comprising electrically stimulating a patient prior to onset of a breathing disorder to activate at least a portion of a diaphragm wherein the stimulation maintains SaO2 at a level that avoids sympathetic nerve activation from a drop in SaO2.
51. A method of treating breathing disorders comprising electrically stimulating a patient prior to onset of a breathing disorder to activate at least a portion of a diaphragm wherein the stimulation maintains SaO2 at a level that prevents arousals from sleep.
52. The method of claim 51 wherein the step of stimulating to maintain SaO2 comprises stimulating to prevent swings in SaO2 prior to onset of a breathing disorder.
53. A method for controlling breathing of a subject comprising:
gradually controlling breathing by providing a plurality of stimulations to provide a plurality of diaphragm activations to gradually decrease the respiratory drive.
54. The method of claim 53 wherein the step of gradually controlling breathing by providing a plurality of diaphragm activations comprises increasing minute ventilation upon each subsequent of the plurality of diaphragm activations.
55. The method of claim 53 wherein the step of gradually controlling breathing by providing a plurality of diaphragm activations comprises gradually decreasing the end of exhalation upon each subsequent of the plurality of diaphragm activations.
56. The method of claim 53 wherein the step of gradually controlling breathing by providing a plurality of diaphragm activations comprises gradually increasing Sao2 and decreasing PCo2 upon each subsequent of the plurality of diaphragm activations.
57. The method of claim 53 further comprising the step of providing therapy stimulation for a period of time after central respiratory drive has been decreased.
58. The method of claim 57 further comprising the step of providing stimulation to normalize breathing
59. The method of claim 57 further comprising the step of providing stimulation to wean patient from stimulation after providing therapy stimulation.
60. A device for controlling breathing of a subject comprising:
an electrical stimulator configured to provide electrical stimulation to activate at least a portion of a diaphragm;
wherein the electrical stimulator further comprises a stimulation protocol configured to gradually control breathing by providing a plurality of stimulations to provide a plurality of diaphragm activations to gradually decrease the respiratory drive.
61. The device of claim 60 wherein the protocol for gradually controlling breathing by providing a plurality of diaphragm activations comprises a protocol for increasing minute ventilation upon each subsequent of the plurality of diaphragm activations.
62. The device of claim 60 wherein the protocol for gradually controlling breathing by providing a plurality of diaphragm activations comprises a protocol for gradually decreasing the end of exhalation upon each subsequent of the plurality of diaphragm activations.
63. The device of claim 60 wherein the protocol for gradually controlling breathing by providing a plurality of diaphragm activations comprises a protocol for gradually increasing Sao2 and decreasing PCo2 upon each subsequent of the plurality of diaphragm activations.
64. The device of claim 60 wherein the protocol further comprises a protocol for providing therapy stimulation for a period of time after central respiratory drive has been decreased.
65. The device of claim 64 further comprising a protocol for providing stimulation to normalize breathing after providing therapy stimulation.
66. The device of claim 64 further comprising a protocol for providing stimulation to wean patient from stimulation after providing therapy stimulation.
67. A method of treating a breathing disorder comprising the steps of:
detecting the breathing disorder;
electrically stimulating to provide respiration when apnea is detected;
wherein the step of electrically stimulating comprises:
initially stimulating to elicit a first minute ventilation that is less than a desired intrinsic minute ventilation; and
then adjusting stimulation to elicit a second minute ventilation that is greater than the first minute ventilation.
68. The method of claim 67 wherein the step of electrically stimulating comprises gradually stimulating to allow for more oxygenation while allowing an increase in PCO2 levels until the respiratory drive increases at least above the apneac threshold.
69. A device for treating apnea comprising:
an apnea detector;
an electrically stimulator configured to provide respiration when apnea is detected;
wherein electrically stimulator further comprises:
a stimulation protocol configured to control stimulation to initially stimulate to elicit a first minute ventilation that is less than a desired intrinsic minute ventilation, and then adjust stimulation to elicit a second minute ventilation that is greater than the first minute ventilation.
70. The device of claim 69 wherein the protocol is configured to control electrical stimulation to gradually stimulate to allow for more oxygenation while allowing an increase in PCO2 levels until the respiratory drive increases at least above the apneac threshold.
71. A method of reducing a breathing rate comprising the steps of:
electrically stimulating a subject to thereby activate at least a portion of a diaphragm so that a breathing rate is reduced.
72. The method of reducing a breathing rate of claim 71 wherein the step of electrically stimulating a subject comprises electrically stimulating to increase inspiration duration.
73. The method of reducing a breathing rate of claim 72 wherein the step of electrically stimulating a subject further comprises maintaining or increasing tidal volume while increasing inspiration duration and maintaining peak flow approximately at or less than an intrinsic peak flow.
74. The method of reducing a breathing rate of claim 71 wherein the step of electrically stimulating a subject comprises augmenting an intrinsic inspiration with stimulation to thereby slow breathing rate.
75. The method of reducing a breathing rate of claim 71 wherein the step of electrically stimulating a subject comprises entraining breathing and then stimulating at a reduced breathing rate.
76. The method of reducing breathing rate of claim 71 wherein the step of electrically stimulating comprises maintaining minute ventilation at or above a normal minute ventilation while reducing breathing rate.
77. A device for reducing a breathing rate comprising:
an electrical stimulator configured to electrically stimulate a subject to activate at least a portion of a diaphragm to elicit a diaphragm response;
wherein the stimulator is programmed with a protocol configured to control electrical stimulation to a subject to reduce a breathing rate.
78. The device of claim 77 wherein the stimulator is programmed with a protocol configured to increase an inspiration duration of a respiration cycle.
79. The device of claim 78 wherein the stimulator is programmed with a protocol configured to control electrical stimulation to maintain or increase tidal volume while increasing inspiration duration and maintaining peak flow approximately at or less than an intrinsic peak flow.
80. The of device claim 77 wherein the stimulator is programmed with a protocol configured to control electrical stimulation to augment an intrinsic inspiration with stimulation to slow a breathing rate.
81. The device of claim 77 wherein the stimulator is programmed with a protocol configured to control electrical stimulation to entrain breathing and then stimulate respiration at a reduced breathing rate.
82. The device of claim 77 wherein the stimulator is programmed with a protocol configured to control electrical stimulation to maintain minute ventilation at or above a normal minute ventilation while reducing breathing rate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/981,727 US20080183239A1 (en) | 2003-10-15 | 2007-10-31 | Breathing therapy device and method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/686,891 US8467876B2 (en) | 2003-10-15 | 2003-10-15 | Breathing disorder detection and therapy delivery device and method |
US10/966,474 US8412331B2 (en) | 2003-10-15 | 2004-10-15 | Breathing therapy device and method |
US11/981,727 US20080183239A1 (en) | 2003-10-15 | 2007-10-31 | Breathing therapy device and method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/966,474 Continuation US8412331B2 (en) | 2003-10-15 | 2004-10-15 | Breathing therapy device and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080183239A1 true US20080183239A1 (en) | 2008-07-31 |
Family
ID=34465515
Family Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/686,891 Active 2026-09-30 US8467876B2 (en) | 2003-10-15 | 2003-10-15 | Breathing disorder detection and therapy delivery device and method |
US10/966,421 Active 2026-02-19 US8255056B2 (en) | 2003-10-15 | 2004-10-15 | Breathing disorder and precursor predictor and therapy delivery device and method |
US10/966,484 Abandoned US20050085869A1 (en) | 2003-10-15 | 2004-10-15 | System and method for mapping diaphragm electrode sites |
US10/966,474 Active 2025-11-29 US8412331B2 (en) | 2003-10-15 | 2004-10-15 | Breathing therapy device and method |
US10/966,472 Active 2026-12-07 US8200336B2 (en) | 2003-10-15 | 2004-10-15 | System and method for diaphragm stimulation |
US10/966,487 Abandoned US20050085734A1 (en) | 2003-10-15 | 2004-10-15 | Heart failure patient treatment and management device |
US11/246,439 Abandoned US20060030894A1 (en) | 2003-10-15 | 2005-10-11 | Breathing disorder detection and therapy device for providing intrinsic breathing |
US11/249,718 Active 2024-09-20 US8348941B2 (en) | 2003-10-15 | 2005-10-13 | Demand-based system for treating breathing disorders |
US11/526,949 Expired - Fee Related US8509901B2 (en) | 2003-10-15 | 2006-09-25 | Device and method for adding to breathing |
US11/981,831 Abandoned US20080183240A1 (en) | 2003-10-15 | 2007-10-31 | Device and method for manipulating minute ventilation |
US11/981,727 Abandoned US20080183239A1 (en) | 2003-10-15 | 2007-10-31 | Breathing therapy device and method |
US11/981,800 Active 2024-12-08 US8116872B2 (en) | 2003-10-15 | 2007-10-31 | Device and method for biasing and stimulating respiration |
US12/080,133 Abandoned US20080188903A1 (en) | 2003-10-15 | 2008-04-01 | Device and method for biasing and stimulating respiration |
US13/851,003 Abandoned US20130296973A1 (en) | 2003-10-15 | 2013-03-26 | Breathing therapy device and method |
US13/915,316 Abandoned US20130296964A1 (en) | 2003-10-15 | 2013-06-11 | Breathing disorder detection and therapy delivery device and method |
Family Applications Before (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/686,891 Active 2026-09-30 US8467876B2 (en) | 2003-10-15 | 2003-10-15 | Breathing disorder detection and therapy delivery device and method |
US10/966,421 Active 2026-02-19 US8255056B2 (en) | 2003-10-15 | 2004-10-15 | Breathing disorder and precursor predictor and therapy delivery device and method |
US10/966,484 Abandoned US20050085869A1 (en) | 2003-10-15 | 2004-10-15 | System and method for mapping diaphragm electrode sites |
US10/966,474 Active 2025-11-29 US8412331B2 (en) | 2003-10-15 | 2004-10-15 | Breathing therapy device and method |
US10/966,472 Active 2026-12-07 US8200336B2 (en) | 2003-10-15 | 2004-10-15 | System and method for diaphragm stimulation |
US10/966,487 Abandoned US20050085734A1 (en) | 2003-10-15 | 2004-10-15 | Heart failure patient treatment and management device |
US11/246,439 Abandoned US20060030894A1 (en) | 2003-10-15 | 2005-10-11 | Breathing disorder detection and therapy device for providing intrinsic breathing |
US11/249,718 Active 2024-09-20 US8348941B2 (en) | 2003-10-15 | 2005-10-13 | Demand-based system for treating breathing disorders |
US11/526,949 Expired - Fee Related US8509901B2 (en) | 2003-10-15 | 2006-09-25 | Device and method for adding to breathing |
US11/981,831 Abandoned US20080183240A1 (en) | 2003-10-15 | 2007-10-31 | Device and method for manipulating minute ventilation |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/981,800 Active 2024-12-08 US8116872B2 (en) | 2003-10-15 | 2007-10-31 | Device and method for biasing and stimulating respiration |
US12/080,133 Abandoned US20080188903A1 (en) | 2003-10-15 | 2008-04-01 | Device and method for biasing and stimulating respiration |
US13/851,003 Abandoned US20130296973A1 (en) | 2003-10-15 | 2013-03-26 | Breathing therapy device and method |
US13/915,316 Abandoned US20130296964A1 (en) | 2003-10-15 | 2013-06-11 | Breathing disorder detection and therapy delivery device and method |
Country Status (3)
Country | Link |
---|---|
US (15) | US8467876B2 (en) |
DE (3) | DE112004001953T5 (en) |
WO (6) | WO2005037366A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085867A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | System and method for diaphragm stimulation |
US20070118183A1 (en) * | 2005-11-18 | 2007-05-24 | Mark Gelfand | System and method to modulate phrenic nerve to prevent sleep apnea |
US20080208282A1 (en) * | 2007-01-22 | 2008-08-28 | Mark Gelfand | Device and method for the treatment of breathing disorders and cardiac disorders |
US20110060380A1 (en) * | 2009-09-10 | 2011-03-10 | Mark Gelfand | Respiratory rectification |
US8265759B2 (en) | 2003-10-15 | 2012-09-11 | Rmx, Llc | Device and method for treating disorders of the cardiovascular system or heart |
US8280513B2 (en) | 2006-12-22 | 2012-10-02 | Rmx, Llc | Device and method to treat flow limitations |
US8335567B2 (en) | 2003-10-15 | 2012-12-18 | Rmx, Llc | Multimode device and method for controlling breathing |
US20130053717A1 (en) * | 2011-08-30 | 2013-02-28 | Nellcor Puritan Bennett Llc | Automatic ventilator challenge to induce spontaneous breathing efforts |
US8433412B1 (en) | 2008-02-07 | 2013-04-30 | Respicardia, Inc. | Muscle and nerve stimulation |
US20130247914A1 (en) * | 2010-11-23 | 2013-09-26 | Koninklijke Philips Electronics N.V. | Obesity hypventilation syndrome treatment system and method |
US20140051938A1 (en) * | 2007-11-26 | 2014-02-20 | David Brian Goldstein | Device to detect and treat Apneas and Hypopnea |
US8844526B2 (en) | 2012-03-30 | 2014-09-30 | Covidien Lp | Methods and systems for triggering with unknown base flow |
US9259573B2 (en) | 2003-10-15 | 2016-02-16 | Rmx, Llc | Device and method for manipulating exhalation |
US9364624B2 (en) | 2011-12-07 | 2016-06-14 | Covidien Lp | Methods and systems for adaptive base flow |
US9370657B2 (en) | 2003-10-15 | 2016-06-21 | Rmx, Llc | Device for manipulating tidal volume and breathing entrainment |
US9498589B2 (en) | 2011-12-31 | 2016-11-22 | Covidien Lp | Methods and systems for adaptive base flow and leak compensation |
US9545511B2 (en) | 2013-11-22 | 2017-01-17 | Simon Fraser University | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US9566436B2 (en) | 2007-01-29 | 2017-02-14 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
US9597509B2 (en) | 2014-01-21 | 2017-03-21 | Simon Fraser University | Systems and related methods for optimization of multi-electrode nerve pacing |
US9649458B2 (en) | 2008-09-30 | 2017-05-16 | Covidien Lp | Breathing assistance system with multiple pressure sensors |
US9776005B2 (en) | 2012-06-21 | 2017-10-03 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US9808591B2 (en) | 2014-08-15 | 2017-11-07 | Covidien Lp | Methods and systems for breath delivery synchronization |
US9925346B2 (en) | 2015-01-20 | 2018-03-27 | Covidien Lp | Systems and methods for ventilation with unknown exhalation flow |
US9950129B2 (en) | 2014-10-27 | 2018-04-24 | Covidien Lp | Ventilation triggering using change-point detection |
US9981096B2 (en) | 2013-03-13 | 2018-05-29 | Covidien Lp | Methods and systems for triggering with unknown inspiratory flow |
US9987488B1 (en) | 2007-06-27 | 2018-06-05 | Respicardia, Inc. | Detecting and treating disordered breathing |
US10039920B1 (en) | 2017-08-02 | 2018-08-07 | Lungpacer Medical, Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10406366B2 (en) | 2006-11-17 | 2019-09-10 | Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US10512772B2 (en) | 2012-03-05 | 2019-12-24 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10857363B2 (en) | 2014-08-26 | 2020-12-08 | Rmx, Llc | Devices and methods for reducing intrathoracic pressure |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US10987511B2 (en) | 2018-11-08 | 2021-04-27 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11266838B1 (en) | 2019-06-21 | 2022-03-08 | Rmx, Llc | Airway diagnostics utilizing phrenic nerve stimulation device and method |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
US11357979B2 (en) | 2019-05-16 | 2022-06-14 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
US11844605B2 (en) | 2016-11-10 | 2023-12-19 | The Research Foundation For Suny | System, method and biomarkers for airway obstruction |
US11883658B2 (en) | 2017-06-30 | 2024-01-30 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
Families Citing this family (270)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060161071A1 (en) | 1997-01-27 | 2006-07-20 | Lynn Lawrence A | Time series objectification system and method |
US9042952B2 (en) | 1997-01-27 | 2015-05-26 | Lawrence A. Lynn | System and method for automatic detection of a plurality of SPO2 time series pattern types |
US8932227B2 (en) | 2000-07-28 | 2015-01-13 | Lawrence A. Lynn | System and method for CO2 and oximetry integration |
US6024089A (en) | 1997-03-14 | 2000-02-15 | Nelcor Puritan Bennett Incorporated | System and method for setting and displaying ventilator alarms |
US9521971B2 (en) | 1997-07-14 | 2016-12-20 | Lawrence A. Lynn | System and method for automatic detection of a plurality of SPO2 time series pattern types |
US9053222B2 (en) | 2002-05-17 | 2015-06-09 | Lawrence A. Lynn | Patient safety processor |
US20060195041A1 (en) | 2002-05-17 | 2006-08-31 | Lynn Lawrence A | Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions |
US7206635B2 (en) * | 2001-06-07 | 2007-04-17 | Medtronic, Inc. | Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
US20080077192A1 (en) | 2002-05-03 | 2008-03-27 | Afferent Corporation | System and method for neuro-stimulation |
DE10248590B4 (en) * | 2002-10-17 | 2016-10-27 | Resmed R&D Germany Gmbh | Method and device for carrying out a signal-processing observation of a measurement signal associated with the respiratory activity of a person |
US7477932B2 (en) | 2003-05-28 | 2009-01-13 | Cardiac Pacemakers, Inc. | Cardiac waveform template creation, maintenance and use |
US7840270B2 (en) | 2003-07-23 | 2010-11-23 | Synapse Biomedical, Inc. | System and method for conditioning a diaphragm of a patient |
US7575553B2 (en) * | 2003-09-18 | 2009-08-18 | Cardiac Pacemakers, Inc. | Methods and systems for assessing pulmonary disease |
US7787946B2 (en) | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
US7887493B2 (en) | 2003-09-18 | 2011-02-15 | Cardiac Pacemakers, Inc. | Implantable device employing movement sensing for detecting sleep-related disorders |
US7510531B2 (en) * | 2003-09-18 | 2009-03-31 | Cardiac Pacemakers, Inc. | System and method for discrimination of central and obstructive disordered breathing events |
US20050107838A1 (en) * | 2003-09-18 | 2005-05-19 | Lovett Eric G. | Subcutaneous cardiac rhythm management with disordered breathing detection and treatment |
US7396333B2 (en) | 2003-08-18 | 2008-07-08 | Cardiac Pacemakers, Inc. | Prediction of disordered breathing |
US7662101B2 (en) * | 2003-09-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Therapy control based on cardiopulmonary status |
US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
US20080161878A1 (en) * | 2003-10-15 | 2008-07-03 | Tehrani Amir J | Device and method to for independently stimulating hemidiaphragms |
US7979128B2 (en) * | 2003-10-15 | 2011-07-12 | Rmx, Llc | Device and method for gradually controlling breathing |
US8140164B2 (en) * | 2003-10-15 | 2012-03-20 | Rmx, Llc | Therapeutic diaphragm stimulation device and method |
US8244358B2 (en) | 2003-10-15 | 2012-08-14 | Rmx, Llc | Device and method for treating obstructive sleep apnea |
US20060167523A1 (en) * | 2003-10-15 | 2006-07-27 | Tehrani Amir J | Device and method for improving upper airway functionality |
US20050085874A1 (en) * | 2003-10-17 | 2005-04-21 | Ross Davis | Method and system for treating sleep apnea |
US20060247693A1 (en) | 2005-04-28 | 2006-11-02 | Yanting Dong | Non-captured intrinsic discrimination in cardiac pacing response classification |
US7319900B2 (en) * | 2003-12-11 | 2008-01-15 | Cardiac Pacemakers, Inc. | Cardiac response classification using multiple classification windows |
US8521284B2 (en) | 2003-12-12 | 2013-08-27 | Cardiac Pacemakers, Inc. | Cardiac response classification using multisite sensing and pacing |
US7774064B2 (en) | 2003-12-12 | 2010-08-10 | Cardiac Pacemakers, Inc. | Cardiac response classification using retriggerable classification windows |
US7421296B1 (en) * | 2004-01-26 | 2008-09-02 | Pacesetter, Inc. | Termination of respiratory oscillations characteristic of Cheyne-Stokes respiration |
US7363085B1 (en) * | 2004-01-26 | 2008-04-22 | Pacesetters, Inc. | Augmenting hypoventilation |
US8942779B2 (en) | 2004-02-05 | 2015-01-27 | Early Sense Ltd. | Monitoring a condition of a subject |
WO2005074361A2 (en) | 2004-02-05 | 2005-08-18 | Earlysense Ltd. | Techniques for prediction and monitoring of respiration-manifested clinical episodes |
US7314451B2 (en) | 2005-04-25 | 2008-01-01 | Earlysense Ltd. | Techniques for prediction and monitoring of clinical episodes |
US8403865B2 (en) | 2004-02-05 | 2013-03-26 | Earlysense Ltd. | Prediction and monitoring of clinical episodes |
US8491492B2 (en) | 2004-02-05 | 2013-07-23 | Earlysense Ltd. | Monitoring a condition of a subject |
US20070118054A1 (en) * | 2005-11-01 | 2007-05-24 | Earlysense Ltd. | Methods and systems for monitoring patients for clinical episodes |
US7751894B1 (en) * | 2004-03-04 | 2010-07-06 | Cardiac Pacemakers, Inc. | Systems and methods for indicating aberrant behavior detected by an implanted medical device |
US20050197588A1 (en) * | 2004-03-04 | 2005-09-08 | Scott Freeberg | Sleep disordered breathing alert system |
US7371220B1 (en) * | 2004-06-30 | 2008-05-13 | Pacesetter, Inc. | System and method for real-time apnea/hypopnea detection using an implantable medical system |
US7269458B2 (en) * | 2004-08-09 | 2007-09-11 | Cardiac Pacemakers, Inc. | Cardiopulmonary functional status assessment via heart rate response detection by implantable cardiac device |
US7389143B2 (en) | 2004-08-12 | 2008-06-17 | Cardiac Pacemakers, Inc. | Cardiopulmonary functional status assessment via metabolic response detection by implantable cardiac device |
JP2006136511A (en) * | 2004-11-12 | 2006-06-01 | Matsushita Electric Ind Co Ltd | Drum type washing/drying machine |
US20090216293A1 (en) * | 2004-11-22 | 2009-08-27 | Mitsuru Sasaki | Apnea preventing stimulation apparatus |
US8473058B2 (en) * | 2004-11-22 | 2013-06-25 | Mitsuru Sasaki | Apnea preventing stimulation apparatus |
US20060122661A1 (en) * | 2004-12-03 | 2006-06-08 | Mandell Lee J | Diaphragmatic pacing with activity monitor adjustment |
US7966072B2 (en) * | 2005-02-18 | 2011-06-21 | Palo Alto Investors | Methods and compositions for treating obesity-hypoventilation syndrome |
US7680534B2 (en) | 2005-02-28 | 2010-03-16 | Cardiac Pacemakers, Inc. | Implantable cardiac device with dyspnea measurement |
US7704211B1 (en) * | 2005-03-21 | 2010-04-27 | Pacesetter, Inc. | Method and apparatus for assessing fluid level in lungs |
US7404799B1 (en) * | 2005-04-05 | 2008-07-29 | Pacesetter, Inc. | System and method for detection of respiration patterns via integration of intracardiac electrogram signals |
US7630763B2 (en) | 2005-04-20 | 2009-12-08 | Cardiac Pacemakers, Inc. | Thoracic or intracardiac impedance detection with automatic vector selection |
US7392086B2 (en) | 2005-04-26 | 2008-06-24 | Cardiac Pacemakers, Inc. | Implantable cardiac device and method for reduced phrenic nerve stimulation |
US7499751B2 (en) * | 2005-04-28 | 2009-03-03 | Cardiac Pacemakers, Inc. | Cardiac signal template generation using waveform clustering |
US8900154B2 (en) * | 2005-05-24 | 2014-12-02 | Cardiac Pacemakers, Inc. | Prediction of thoracic fluid accumulation |
US20060271121A1 (en) | 2005-05-25 | 2006-11-30 | Cardiac Pacemakers, Inc. | Closed loop impedance-based cardiac resynchronization therapy systems, devices, and methods |
US7644714B2 (en) | 2005-05-27 | 2010-01-12 | Apnex Medical, Inc. | Devices and methods for treating sleep disorders |
US8364455B2 (en) * | 2005-06-09 | 2013-01-29 | Maquet Critical Care Ab | Simulator for use with a breathing-assist device |
US8036750B2 (en) | 2005-06-13 | 2011-10-11 | Cardiac Pacemakers, Inc. | System for neural control of respiration |
US20070021678A1 (en) * | 2005-07-19 | 2007-01-25 | Cardiac Pacemakers, Inc. | Methods and apparatus for monitoring physiological responses to steady state activity |
US9839781B2 (en) | 2005-08-22 | 2017-12-12 | Cardiac Pacemakers, Inc. | Intracardiac impedance and its applications |
US8494618B2 (en) * | 2005-08-22 | 2013-07-23 | Cardiac Pacemakers, Inc. | Intracardiac impedance and its applications |
US20070044669A1 (en) * | 2005-08-24 | 2007-03-01 | Geise Gregory D | Aluminum can compacting mechanism with improved actuation handle assembly |
US9050005B2 (en) * | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
US7731663B2 (en) | 2005-09-16 | 2010-06-08 | Cardiac Pacemakers, Inc. | System and method for generating a trend parameter based on respiration rate distribution |
US7974691B2 (en) * | 2005-09-21 | 2011-07-05 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling cardiac resynchronization therapy using cardiac impedance |
JP2009515174A (en) * | 2005-11-04 | 2009-04-09 | レスメド・リミテッド | Method and apparatus for supporting diagnosis and management of sleep breathing disorders |
EP1960040B1 (en) * | 2005-12-01 | 2017-02-08 | Second Sight Medical Products, Inc. | Fitting a neural prosthesis using impedance and electrode height |
US7766840B2 (en) * | 2005-12-01 | 2010-08-03 | Cardiac Pacemakers, Inc. | Method and system for heart failure status evaluation based on a disordered breathing index |
CA2631915A1 (en) * | 2005-12-02 | 2007-06-07 | Synapse Biomedical, Inc. | Transvisceral neurostimulation mapping device and method |
US8281792B2 (en) * | 2005-12-31 | 2012-10-09 | John W Royalty | Electromagnetic diaphragm assist device and method for assisting a diaphragm function |
US8676323B2 (en) * | 2006-03-09 | 2014-03-18 | Synapse Biomedical, Inc. | Ventilatory assist system and methods to improve respiratory function |
WO2007115118A1 (en) * | 2006-03-29 | 2007-10-11 | Catholic Healthcare West | Vagus nerve stimulation method |
US8021310B2 (en) | 2006-04-21 | 2011-09-20 | Nellcor Puritan Bennett Llc | Work of breathing display for a ventilation system |
WO2007136266A1 (en) * | 2006-05-23 | 2007-11-29 | Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce | Medical probe |
KR100845464B1 (en) * | 2006-06-14 | 2008-07-10 | (주)머티리얼솔루션테크놀로지 | Implantable diaphragm stimulator and breathing pacemaker using the same |
US20080071185A1 (en) * | 2006-08-08 | 2008-03-20 | Cardiac Pacemakers, Inc. | Periodic breathing during activity |
US8226570B2 (en) | 2006-08-08 | 2012-07-24 | Cardiac Pacemakers, Inc. | Respiration monitoring for heart failure using implantable device |
US8103341B2 (en) | 2006-08-25 | 2012-01-24 | Cardiac Pacemakers, Inc. | System for abating neural stimulation side effects |
US8121692B2 (en) | 2006-08-30 | 2012-02-21 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation with respiratory feedback |
US8050765B2 (en) | 2006-08-30 | 2011-11-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling neural stimulation during disordered breathing |
JP5236647B2 (en) * | 2006-09-11 | 2013-07-17 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | System and method for electrode placement on patient body |
US8209013B2 (en) | 2006-09-14 | 2012-06-26 | Cardiac Pacemakers, Inc. | Therapeutic electrical stimulation that avoids undesirable activation |
US7784461B2 (en) | 2006-09-26 | 2010-08-31 | Nellcor Puritan Bennett Llc | Three-dimensional waveform display for a breathing assistance system |
US20080072902A1 (en) * | 2006-09-27 | 2008-03-27 | Nellcor Puritan Bennett Incorporated | Preset breath delivery therapies for a breathing assistance system |
AU2007313319B2 (en) | 2006-10-13 | 2012-03-22 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US9186511B2 (en) | 2006-10-13 | 2015-11-17 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US9913982B2 (en) | 2011-01-28 | 2018-03-13 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US9205262B2 (en) | 2011-05-12 | 2015-12-08 | Cyberonics, Inc. | Devices and methods for sleep apnea treatment |
US9744354B2 (en) | 2008-12-31 | 2017-08-29 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US8855771B2 (en) | 2011-01-28 | 2014-10-07 | Cyberonics, Inc. | Screening devices and methods for obstructive sleep apnea therapy |
US20080109047A1 (en) * | 2006-10-26 | 2008-05-08 | Pless Benjamin D | Apnea treatment device |
US7917194B1 (en) * | 2006-11-15 | 2011-03-29 | Pacesetter, Inc. | Method and apparatus for detecting pulmonary edema |
US9968266B2 (en) | 2006-12-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Risk stratification based heart failure detection algorithm |
US8417328B2 (en) * | 2007-02-01 | 2013-04-09 | Ls Biopath, Inc. | Electrical systems for detection and characterization of abnormal tissue and cells |
EP2174118A4 (en) * | 2007-02-01 | 2015-06-24 | Ls Biopath Inc | Optical system for identification and characterization of abnormal tissue and cells |
US9079016B2 (en) * | 2007-02-05 | 2015-07-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
WO2008123903A1 (en) * | 2007-02-09 | 2008-10-16 | Mayo Foundation For Medical Education And Research | Peripheral oxistimulator apparatus and methods |
US20080228093A1 (en) * | 2007-03-13 | 2008-09-18 | Yanting Dong | Systems and methods for enhancing cardiac signal features used in morphology discrimination |
US20080234556A1 (en) * | 2007-03-20 | 2008-09-25 | Cardiac Pacemakers, Inc. | Method and apparatus for sensing respiratory activities using sensor in lymphatic system |
US20080243016A1 (en) * | 2007-03-28 | 2008-10-02 | Cardiac Pacemakers, Inc. | Pulmonary Artery Pressure Signals And Methods of Using |
US11259802B2 (en) * | 2007-04-13 | 2022-03-01 | Covidien Lp | Powered surgical instrument |
US7950560B2 (en) * | 2007-04-13 | 2011-05-31 | Tyco Healthcare Group Lp | Powered surgical instrument |
US8585607B2 (en) | 2007-05-02 | 2013-11-19 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
US8821418B2 (en) | 2007-05-02 | 2014-09-02 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
US9820671B2 (en) * | 2007-05-17 | 2017-11-21 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
EP2152362B1 (en) * | 2007-05-28 | 2015-07-08 | St. Jude Medical AB | Implantable medical device for monitoring lung deficiency |
US8983609B2 (en) | 2007-05-30 | 2015-03-17 | The Cleveland Clinic Foundation | Apparatus and method for treating pulmonary conditions |
US20090024176A1 (en) * | 2007-07-17 | 2009-01-22 | Joonkyoo Anthony Yun | Methods and devices for producing respiratory sinus arrhythmia |
US20090024047A1 (en) * | 2007-07-20 | 2009-01-22 | Cardiac Pacemakers, Inc. | Devices and methods for respiration therapy |
US9037239B2 (en) | 2007-08-07 | 2015-05-19 | Cardiac Pacemakers, Inc. | Method and apparatus to perform electrode combination selection |
US8265736B2 (en) | 2007-08-07 | 2012-09-11 | Cardiac Pacemakers, Inc. | Method and apparatus to perform electrode combination selection |
EP2210639A3 (en) * | 2007-08-22 | 2014-08-06 | The Research Foundation Of State University Of New York | Breathing-gas delivery and sharing system |
US8135471B2 (en) * | 2007-08-28 | 2012-03-13 | Cardiac Pacemakers, Inc. | Method and apparatus for inspiratory muscle stimulation using implantable device |
US20090076346A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Tracking and Security for Adherent Patient Monitor |
WO2009036256A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Injectable physiological monitoring system |
US8897868B2 (en) | 2007-09-14 | 2014-11-25 | Medtronic, Inc. | Medical device automatic start-up upon contact to patient tissue |
EP2194864B1 (en) | 2007-09-14 | 2018-08-29 | Medtronic Monitoring, Inc. | System and methods for wireless body fluid monitoring |
US8460189B2 (en) | 2007-09-14 | 2013-06-11 | Corventis, Inc. | Adherent cardiac monitor with advanced sensing capabilities |
EP2200512A1 (en) | 2007-09-14 | 2010-06-30 | Corventis, Inc. | Adherent device for respiratory monitoring and sleep disordered breathing |
US8116841B2 (en) | 2007-09-14 | 2012-02-14 | Corventis, Inc. | Adherent device with multiple physiological sensors |
WO2009048610A1 (en) | 2007-10-10 | 2009-04-16 | Cardiac Pacemakers, Inc. | Respiratory stimulation for treating periodic breathing |
EP2210226A4 (en) * | 2007-10-12 | 2013-11-06 | Patientslikeme Inc | Self-improving method of using online communities to predict health-related outcomes |
WO2009059033A1 (en) * | 2007-10-30 | 2009-05-07 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
US8155744B2 (en) | 2007-12-13 | 2012-04-10 | The Cleveland Clinic Foundation | Neuromodulatory methods for treating pulmonary disorders |
US8346349B2 (en) * | 2008-01-16 | 2013-01-01 | Massachusetts Institute Of Technology | Method and apparatus for predicting patient outcomes from a physiological segmentable patient signal |
EP2254661B1 (en) | 2008-02-14 | 2015-10-07 | Cardiac Pacemakers, Inc. | Apparatus for phrenic stimulation detection |
EP2257216B1 (en) * | 2008-03-12 | 2021-04-28 | Medtronic Monitoring, Inc. | Heart failure decompensation prediction based on cardiac rhythm |
US20110054279A1 (en) * | 2008-03-27 | 2011-03-03 | Widemed Ltd. | Diagnosis of periodic breathing |
US8412317B2 (en) | 2008-04-18 | 2013-04-02 | Corventis, Inc. | Method and apparatus to measure bioelectric impedance of patient tissue |
US9883809B2 (en) | 2008-05-01 | 2018-02-06 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
US8882684B2 (en) | 2008-05-12 | 2014-11-11 | Earlysense Ltd. | Monitoring, predicting and treating clinical episodes |
JP5474937B2 (en) | 2008-05-07 | 2014-04-16 | ローレンス エー. リン, | Medical disorder pattern search engine |
EP3708219B1 (en) | 2008-05-15 | 2022-08-03 | Inspire Medical Systems, Inc. | Apparatus for sensing respiratory pressure in an implantable stimulation system |
US8229566B2 (en) * | 2008-06-25 | 2012-07-24 | Sheng Li | Method and apparatus of breathing-controlled electrical stimulation for skeletal muscles |
US8340746B2 (en) * | 2008-07-17 | 2012-12-25 | Massachusetts Institute Of Technology | Motif discovery in physiological datasets: a methodology for inferring predictive elements |
US8047999B2 (en) | 2008-09-19 | 2011-11-01 | Medtronic, Inc. | Filtering of a physiologic signal in a medical device |
EP2331201B1 (en) | 2008-10-01 | 2020-04-29 | Inspire Medical Systems, Inc. | System for treating sleep apnea transvenously |
US20100087893A1 (en) * | 2008-10-03 | 2010-04-08 | Solange Pasquet | Operant Conditioning-Based Device for Snoring and Obstructive Sleep Apnea and Method of Use |
US8644939B2 (en) * | 2008-11-18 | 2014-02-04 | Neurostream Technologies General Partnership | Method and device for the detection, identification and treatment of sleep apnea/hypopnea |
EP3184045B1 (en) * | 2008-11-19 | 2023-12-06 | Inspire Medical Systems, Inc. | System treating sleep disordered breathing |
WO2010077851A2 (en) | 2008-12-15 | 2010-07-08 | Corventis, Inc. | Patient monitoring systems and methods |
EP2198779B1 (en) * | 2008-12-22 | 2018-09-19 | Sendsor GmbH | Device and method for early detection of exacerbations |
US20100204567A1 (en) * | 2009-02-09 | 2010-08-12 | The Cleveland Clinic Foundation | Ultrasound-guided delivery of a therapy delivery device to a phrenic nerve |
US8870773B2 (en) * | 2009-02-09 | 2014-10-28 | The Cleveland Clinic Foundation | Ultrasound-guided delivery of a therapy delivery device to a nerve target |
US9486628B2 (en) | 2009-03-31 | 2016-11-08 | Inspire Medical Systems, Inc. | Percutaneous access for systems and methods of treating sleep apnea |
AU2010242036A1 (en) | 2009-04-30 | 2011-11-03 | Patientslikeme, Inc. | Systems and methods for encouragement of data submission in online communities |
US8378832B2 (en) * | 2009-07-09 | 2013-02-19 | Harry J. Cassidy | Breathing disorder treatment system and method |
WO2011008748A2 (en) | 2009-07-15 | 2011-01-20 | Cardiac Pacemakers, Inc. | Remote pace detection in an implantable medical device |
EP2453975B1 (en) | 2009-07-15 | 2016-11-02 | Cardiac Pacemakers, Inc. | Remote sensing in an implantable medical device |
EP2453977B1 (en) * | 2009-07-15 | 2017-11-08 | Cardiac Pacemakers, Inc. | Physiological vibration detection in an implanted medical device |
EP2470065A1 (en) * | 2009-08-28 | 2012-07-04 | Lynn, Lawrence Allan | Relational thermorespirometer spot vitals monitor |
US9072899B1 (en) * | 2009-09-04 | 2015-07-07 | Todd Nickloes | Diaphragm pacemaker |
AU2010291938B2 (en) * | 2009-09-14 | 2016-03-10 | Sleep Methods, Inc. | System and method for training and promoting a conditioned reflex intervention during sleep |
WO2011050283A2 (en) | 2009-10-22 | 2011-04-28 | Corventis, Inc. | Remote detection and monitoring of functional chronotropic incompetence |
US8409108B2 (en) * | 2009-11-05 | 2013-04-02 | Inovise Medical, Inc. | Multi-axial heart sounds and murmur detection for hemodynamic-condition assessment |
USD638852S1 (en) | 2009-12-04 | 2011-05-31 | Nellcor Puritan Bennett Llc | Ventilator display screen with an alarm icon |
USD649157S1 (en) | 2009-12-04 | 2011-11-22 | Nellcor Puritan Bennett Llc | Ventilator display screen with a user interface |
US9119925B2 (en) | 2009-12-04 | 2015-09-01 | Covidien Lp | Quick initiation of respiratory support via a ventilator user interface |
US8924878B2 (en) | 2009-12-04 | 2014-12-30 | Covidien Lp | Display and access to settings on a ventilator graphical user interface |
US8335992B2 (en) | 2009-12-04 | 2012-12-18 | Nellcor Puritan Bennett Llc | Visual indication of settings changes on a ventilator graphical user interface |
US9451897B2 (en) | 2009-12-14 | 2016-09-27 | Medtronic Monitoring, Inc. | Body adherent patch with electronics for physiologic monitoring |
US9262588B2 (en) | 2009-12-18 | 2016-02-16 | Covidien Lp | Display of respiratory data graphs on a ventilator graphical user interface |
US8499252B2 (en) | 2009-12-18 | 2013-07-30 | Covidien Lp | Display of respiratory data graphs on a ventilator graphical user interface |
JP2011213096A (en) * | 2010-03-19 | 2011-10-27 | Makita Corp | Power tool |
US8965498B2 (en) | 2010-04-05 | 2015-02-24 | Corventis, Inc. | Method and apparatus for personalized physiologic parameters |
US11723542B2 (en) * | 2010-08-13 | 2023-08-15 | Respiratory Motion, Inc. | Advanced respiratory monitor and system |
US8983572B2 (en) | 2010-10-29 | 2015-03-17 | Inspire Medical Systems, Inc. | System and method for patient selection in treating sleep disordered breathing |
US8585604B2 (en) | 2010-10-29 | 2013-11-19 | Medtronic, Inc. | Integrated patient care |
KR20120046554A (en) * | 2010-11-02 | 2012-05-10 | 연세대학교 산학협력단 | Sensor for detecting cancer tissue and manufacturing method of the same |
US9186504B2 (en) | 2010-11-15 | 2015-11-17 | Rainbow Medical Ltd | Sleep apnea treatment |
US9457186B2 (en) | 2010-11-15 | 2016-10-04 | Bluewind Medical Ltd. | Bilateral feedback |
US10292625B2 (en) | 2010-12-07 | 2019-05-21 | Earlysense Ltd. | Monitoring a sleeping subject |
US20120157799A1 (en) * | 2010-12-20 | 2012-06-21 | Abhilash Patangay | Using device based sensors to classify events and generate alerts |
US8827930B2 (en) * | 2011-01-10 | 2014-09-09 | Bioguidance Llc | System and method for patient monitoring |
US9744349B2 (en) | 2011-02-10 | 2017-08-29 | Respicardia, Inc. | Medical lead and implantation |
US10342939B2 (en) * | 2011-03-23 | 2019-07-09 | ResMed Pty Ltd | Detection of ventilation sufficiency |
EP2713870A4 (en) * | 2011-06-03 | 2014-10-22 | Los Angeles Childrens Hospital | Electrophysiological diagnosis and treatment for asthma |
US8706235B2 (en) | 2011-07-27 | 2014-04-22 | Medtronic, Inc. | Transvenous method to induce respiration |
US8478413B2 (en) | 2011-07-27 | 2013-07-02 | Medtronic, Inc. | Bilateral phrenic nerve stimulation with reduced dyssynchrony |
US9861817B2 (en) | 2011-07-28 | 2018-01-09 | Medtronic, Inc. | Medical device to provide breathing therapy |
US8509902B2 (en) | 2011-07-28 | 2013-08-13 | Medtronic, Inc. | Medical device to provide breathing therapy |
JP6092212B2 (en) | 2011-08-11 | 2017-03-08 | インスパイア・メディカル・システムズ・インコーポレイテッドInspire Medical Systems, Inc. | System for selecting a stimulation protocol based on detection results of respiratory effort |
US8934992B2 (en) | 2011-09-01 | 2015-01-13 | Inspire Medical Systems, Inc. | Nerve cuff |
US8855783B2 (en) | 2011-09-09 | 2014-10-07 | Enopace Biomedical Ltd. | Detector-based arterial stimulation |
GB201116860D0 (en) * | 2011-09-30 | 2011-11-09 | Guy S And St Thomas Nhs Foundation Trust | Patent monitoring method and monitoring device |
CN104508343B (en) | 2012-01-26 | 2016-11-16 | Med-El电气医疗器械有限公司 | For treating the Neural monitoring method and system of pharyngeal obstacle |
WO2013112853A1 (en) * | 2012-01-27 | 2013-08-01 | T4 Analytics Llc | Anesthesia monitoring systems and methods of monitoring anesthesia |
US20130197385A1 (en) * | 2012-01-31 | 2013-08-01 | Medtronic, Inc. | Respiratory function detection |
BR112014027983B1 (en) | 2012-05-08 | 2022-05-24 | Aeromics, Inc | Use of selective aquaporin inhibitors |
US20150165207A1 (en) * | 2012-07-02 | 2015-06-18 | Medisci L.L.C. | Method and device for respiratory and cardiorespiratory support |
US10362967B2 (en) | 2012-07-09 | 2019-07-30 | Covidien Lp | Systems and methods for missed breath detection and indication |
CN104661588B (en) * | 2012-07-27 | 2017-03-08 | 心脏起搏器股份公司 | Heart failure patient is layered |
CN102949770B (en) * | 2012-11-09 | 2015-04-22 | 张红璇 | External diaphragm pacing and breathing machine synergistic air supply method and device thereof |
WO2014099820A1 (en) * | 2012-12-19 | 2014-06-26 | Inovise Medical, Inc. | Hemodynamic performance enhancement through asymptomatic diaphragm stimulation |
US10335592B2 (en) | 2012-12-19 | 2019-07-02 | Viscardia, Inc. | Systems, devices, and methods for improving hemodynamic performance through asymptomatic diaphragm stimulation |
CN103055417B (en) * | 2012-12-31 | 2015-09-09 | 中国人民解放军第三军医大学第一附属医院 | A kind of noinvasive transcutaneous electrostimulation instrument |
US20170112409A1 (en) * | 2013-02-06 | 2017-04-27 | BTS S.p.A. | Wireless probe for dental electromyography |
TWI505812B (en) * | 2013-04-15 | 2015-11-01 | Chi Mei Comm Systems Inc | System and method for displaying analysis of breath |
US9295397B2 (en) | 2013-06-14 | 2016-03-29 | Massachusetts Institute Of Technology | Method and apparatus for beat-space frequency domain prediction of cardiovascular death after acute coronary event |
WO2015020979A1 (en) | 2013-08-05 | 2015-02-12 | Cardiac Pacemakers, Inc. | System and method for detecting worsening of heart failure based on rapid shallow breathing index |
WO2015021348A2 (en) | 2013-08-09 | 2015-02-12 | Inspire Medical Systems, Inc. | Patient control for implantable medical device |
EP2839859B1 (en) * | 2013-08-20 | 2016-04-27 | Sorin CRM SAS | Active medical device, in particular a CRT resynchroniser, including predictive warning means for cardiac decompensation in the presence of central sleep apnoea |
KR20160067152A (en) * | 2013-10-02 | 2016-06-13 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | Organ mounted electronics |
CN112402434A (en) | 2013-11-06 | 2021-02-26 | 埃罗米克斯公司 | New formula |
WO2015069949A1 (en) | 2013-11-07 | 2015-05-14 | Safeop Surgical, Inc. | Systems and methods for detecting nerve function |
EP3071288B1 (en) | 2013-11-19 | 2018-11-14 | The Cleveland Clinic Foundation | System for treating obstructive sleep apnea using a neuromuscular stimulator |
WO2015095969A1 (en) * | 2013-12-27 | 2015-07-02 | St. Michael's Hospital | Device, method and system for providing ventilatory assist to a patient |
EP4241662A1 (en) | 2014-02-11 | 2023-09-13 | Cyberonics, Inc. | Systems for detecting and treating obstructive sleep apnea |
CN103800999A (en) * | 2014-02-25 | 2014-05-21 | 郑州雅晨生物科技有限公司 | Obstructive sleep apnea hypopnea syndrome therapeutic apparatus |
TWI645835B (en) | 2014-02-25 | 2019-01-01 | 萊鎂醫療器材股份有限公司 | Breathing airflow detecting device, method and application thereof |
JP6585609B2 (en) * | 2014-02-28 | 2019-10-02 | パウエル マンスフィールド, インコーポレイテッド | System for sensing EMG activity |
US20150283382A1 (en) * | 2014-04-04 | 2015-10-08 | Med-El Elektromedizinische Geraete Gmbh | Respiration Sensors For Recording Of Triggered Respiratory Signals In Neurostimulators |
US11141070B2 (en) | 2014-07-22 | 2021-10-12 | Teijin Pharma Limited | Heart failure evaluation method and diagnosis device |
US9659159B2 (en) | 2014-08-14 | 2017-05-23 | Sleep Data Services, Llc | Sleep data chain of custody |
US10172593B2 (en) | 2014-09-03 | 2019-01-08 | Earlysense Ltd. | Pregnancy state monitoring |
KR102410215B1 (en) * | 2014-10-08 | 2022-06-17 | 엘지전자 주식회사 | Digital device and method for controlling same |
CN106999118B (en) | 2014-10-13 | 2020-07-17 | 葡萄糖传感器公司 | Analyte sensing device |
CA2966197C (en) | 2014-10-31 | 2023-04-11 | Avent, Inc. | Non-invasive nerve stimulation system and method |
EP3064131A1 (en) * | 2015-03-03 | 2016-09-07 | BIOTRONIK SE & Co. KG | Combined vagus-phrenic nerve stimulation apparatus |
EP3881892A1 (en) | 2015-03-19 | 2021-09-22 | Inspire Medical Systems, Inc. | Stimulation for treating sleep disordered breathing |
US9839786B2 (en) | 2015-04-17 | 2017-12-12 | Inspire Medical Systems, Inc. | System and method of monitoring for and reporting on patient-made stimulation therapy programming changes |
EP3334338B1 (en) * | 2015-08-11 | 2019-07-17 | Koninklijke Philips N.V. | Apparatus and method for processing electromyography signals related to respiratory activity |
EP3405103B1 (en) * | 2016-01-20 | 2021-10-27 | Soniphi LLC | Frequency analysis feedback system |
EP3445872A1 (en) | 2016-04-20 | 2019-02-27 | Glusense Ltd. | Fret-based glucose-detection molecules |
CN105748069B (en) * | 2016-04-21 | 2018-10-23 | 罗远明 | A kind of centric sleep apnea carbon dioxide inhalation therapy device |
CN105879223B (en) * | 2016-04-22 | 2017-02-08 | 广州雪利昂生物科技有限公司 | Method and apparatus for triggering external diaphragm pacemaker by using surface electromyogram signal as synchronization signal |
US10369361B2 (en) | 2016-04-29 | 2019-08-06 | Viscardia, Inc. | Leads for implantable medical device that affects pressures within the intrathoracic cavity through diaphragmatic stimulation |
US11247039B2 (en) | 2016-05-03 | 2022-02-15 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
US10583287B2 (en) | 2016-05-23 | 2020-03-10 | Btl Medical Technologies S.R.O. | Systems and methods for tissue treatment |
US10556122B1 (en) | 2016-07-01 | 2020-02-11 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
WO2018022658A1 (en) * | 2016-07-25 | 2018-02-01 | Ctrl-Labs Corporation | Adaptive system for deriving control signals from measurements of neuromuscular activity |
US11399770B2 (en) | 2016-08-01 | 2022-08-02 | Med-El Elektromedizinische Geraete Gmbh | Respiratory triggered parasternal electromyographic recording in neurostimulators |
US11052241B2 (en) * | 2016-11-03 | 2021-07-06 | West Affum Holdings Corp. | Wearable cardioverter defibrillator (WCD) system measuring patient's respiration |
US11426513B2 (en) * | 2016-11-29 | 2022-08-30 | Geoffrey Louis Tyson | Implantable devices for drug delivery in response to detected biometric parameters associated with an opioid drug overdose and associated systems and methods |
CN107019495B (en) * | 2017-03-13 | 2019-11-29 | 北京航空航天大学 | Apnea detection and prior-warning device and method based on smart phone and the mounted respiration transducer of nose |
JP7187473B2 (en) | 2017-03-22 | 2022-12-12 | セーフオプ サージカル インコーポレイテッド | Medical system and method for detecting changes in electrophysiological evoked potentials |
CN110868911B (en) | 2017-04-29 | 2022-10-11 | 心脏起搏器股份公司 | Heart failure event rate assessment |
EP3760280A1 (en) * | 2017-06-16 | 2021-01-06 | Alphatec Spine, Inc. | Systems, methods, and devices for detecting the threshold of nerve-muscle response using variable frequency stimulation |
EP3664889B1 (en) | 2017-08-11 | 2024-02-21 | Inspire Medical Systems, Inc. | Cuff electrode |
WO2019046547A1 (en) | 2017-08-31 | 2019-03-07 | Mayo Foundation For Medical Education And Research | Systems and methods for controlling breathing |
CN108174034A (en) * | 2017-12-27 | 2018-06-15 | 苏鹏霄 | Using the system and method for APP real time monitoring sacral nerve neuromodulation devices |
US11031134B2 (en) * | 2018-02-05 | 2021-06-08 | International Business Machines Corporation | Monitoring individuals for water retention management |
US10722710B2 (en) | 2018-03-24 | 2020-07-28 | Moshe Hayik | Secretion clearance and cough assist |
US11058349B2 (en) | 2018-03-24 | 2021-07-13 | Ovadia Sagiv | Non-invasive handling of sleep apnea, snoring and emergency situations |
JP7167132B2 (en) * | 2018-03-26 | 2022-11-08 | テルモ株式会社 | A support system, a support method, a support program, and a recording medium recording the support program |
US11109787B2 (en) * | 2018-05-21 | 2021-09-07 | Vine Medical LLC | Multi-tip probe for obtaining bioelectrical measurements |
US11771899B2 (en) | 2018-07-10 | 2023-10-03 | The Cleveland Clinic Foundation | System and method for treating obstructive sleep apnea |
US11633560B2 (en) | 2018-11-10 | 2023-04-25 | Novaresp Technologies Inc. | Method and apparatus for continuous management of airway pressure for detection and/or prediction of respiratory failure |
US11894139B1 (en) | 2018-12-03 | 2024-02-06 | Patientslikeme Llc | Disease spectrum classification |
US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
US11382563B2 (en) | 2019-03-01 | 2022-07-12 | Respiration AI, LLC | System and method for detecting ventilatory depression and for prompting a patient to breathe |
US11547307B2 (en) * | 2019-04-29 | 2023-01-10 | Technion Research And Development Foundation Ltd. | Quantification of the respiratory effort from hemodynamic measurements |
US11351380B2 (en) | 2019-05-02 | 2022-06-07 | Xii Medical, Inc. | Implantable stimulation power receiver, systems and methods |
US20200375665A1 (en) * | 2019-05-31 | 2020-12-03 | Canon U.S.A., Inc. | Medical continuum robot and methods thereof |
KR20210024874A (en) | 2019-08-26 | 2021-03-08 | 삼성전자주식회사 | Monitoring device inserted into human body and operating method thereof |
US11524158B2 (en) | 2019-09-26 | 2022-12-13 | Viscardia, Inc. | Implantable medical systems, devices, and methods for affecting cardiac function through diaphragm stimulation, and for monitoring diaphragmatic health |
US11420061B2 (en) | 2019-10-15 | 2022-08-23 | Xii Medical, Inc. | Biased neuromodulation lead and method of using same |
WO2021141950A1 (en) * | 2020-01-06 | 2021-07-15 | W. L. Gore & Associates, Inc. | Conditioning algorithms for biomarker sensor measurements |
EP4069343A4 (en) * | 2020-02-26 | 2024-02-21 | Novaresp Tech Inc | Method and apparatus for determining and/or predicting sleep and respiratory behaviours for management of airway pressure |
WO2021194874A1 (en) | 2020-03-27 | 2021-09-30 | Viscardia, Inc. | Implantable medical systems, devices and methods for delivering asymptomatic diaphragmatic stimulation |
US11878167B2 (en) | 2020-05-04 | 2024-01-23 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
KR20230000081U (en) | 2020-05-04 | 2023-01-10 | 비티엘 헬쓰케어 테크놀로지스 에이.에스. | Device and method for unattended treatment of patients |
US11672934B2 (en) | 2020-05-12 | 2023-06-13 | Covidien Lp | Remote ventilator adjustment |
US11691010B2 (en) | 2021-01-13 | 2023-07-04 | Xii Medical, Inc. | Systems and methods for improving sleep disordered breathing |
CN116963800A (en) * | 2021-02-24 | 2023-10-27 | 美敦力公司 | Impedance-based electrode selection for sensing or stimulation |
US11896816B2 (en) | 2021-11-03 | 2024-02-13 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
CN114376559B (en) * | 2022-01-18 | 2023-09-19 | 高昌生医股份有限公司 | Respiratory datum line tracking acceleration method |
US20240050743A1 (en) * | 2022-08-11 | 2024-02-15 | Stimdia Medical, Inc. | Apparatus and method for diaphragm stimulation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6415183B1 (en) * | 1999-12-09 | 2002-07-02 | Cardiac Pacemakers, Inc. | Method and apparatus for diaphragmatic pacing |
US20050261747A1 (en) * | 2003-05-16 | 2005-11-24 | Schuler Eleanor L | Method and system to control respiration by means of neuro-electrical coded signals |
US20060122661A1 (en) * | 2004-12-03 | 2006-06-08 | Mandell Lee J | Diaphragmatic pacing with activity monitor adjustment |
US7117032B2 (en) * | 1999-03-01 | 2006-10-03 | Quantum Intech, Inc. | Systems and methods for facilitating physiological coherence using respiration training |
US20060224211A1 (en) * | 2005-03-31 | 2006-10-05 | Durand Dominique M | Method of treating obstructive sleep apnea using electrical nerve stimulation |
US20060282131A1 (en) * | 2005-06-13 | 2006-12-14 | Cardiac Pacemakers, Inc. | System for neural control of respiration |
Family Cites Families (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US101833A (en) * | 1870-04-12 | Improved coal-box | ||
US61320A (en) * | 1867-01-22 | of lewiston | ||
US61315A (en) * | 1867-01-22 | Improved apparatus for decomposing animal and vegetable substances | ||
US85734A (en) * | 1869-01-12 | Improvement in gr | ||
US61319A (en) * | 1867-01-22 | Improvement in pumps | ||
US99479A (en) * | 1870-02-01 | Edwin r | ||
US21795A (en) * | 1858-10-12 | Improvement in cotton-gins | ||
US540731A (en) * | 1895-06-11 | Wire-reel | ||
US176809A (en) * | 1876-05-02 | Improvement in machinery for cutting waved edges on leather | ||
US39745A (en) * | 1863-09-01 | Improvement in hoisting apparatus | ||
US167523A (en) * | 1875-09-07 | Improvement in sole-channeling machines | ||
US155341A (en) * | 1874-09-22 | Improvement in fertilizers | ||
US240240A (en) * | 1881-04-19 | Beer-faucet | ||
US237963A (en) * | 1881-02-22 | Manufacture of sheet-iron | ||
US127091A (en) * | 1872-05-21 | Improvement in spark-arresters | ||
US142815A (en) * | 1873-09-16 | Improvement in car-couplings | ||
US115561A (en) * | 1871-06-06 | Improvement in electro-sviagnetic separators | ||
US138719A (en) * | 1873-05-06 | Improvement in fly-switches | ||
US149334A (en) * | 1874-04-07 | Improvement in railroad-frogs | ||
US88015A (en) * | 1869-03-23 | Improvement in lifting-jacks | ||
US85866A (en) * | 1869-01-12 | Improved bed-bottom | ||
US85868A (en) * | 1869-01-12 | Improvement in steam water-elevators | ||
US522862A (en) * | 1894-07-10 | Sawhorse | ||
US74741A (en) * | 1868-02-18 | George w | ||
US204213A (en) * | 1878-05-28 | Improvement in loom-pickers | ||
US247729A (en) * | 1881-09-27 | Corset-stay | ||
US111040A (en) * | 1871-01-17 | Improvement in fluid-meters | ||
US85865A (en) * | 1869-01-12 | Improvement in threshing-knives | ||
US193697A (en) * | 1877-07-31 | Improvement in mowers | ||
US174287A (en) * | 1876-02-29 | Improvement in tool-holders | ||
US300094A (en) * | 1884-06-10 | Machine | ||
US345202A (en) * | 1886-07-06 | Treating lac | ||
US85869A (en) * | 1869-01-12 | Improvement in horse-rakes | ||
US146918A (en) * | 1874-01-27 | Improvement in car-couplings | ||
US65563A (en) * | 1867-06-11 | Julius hackert | ||
US85867A (en) * | 1869-01-12 | Improvement in blind-fastener | ||
US119711A (en) * | 1871-10-10 | Improvement in staple-machines | ||
US540733A (en) * | 1895-06-11 | Ernst gerstenberg and herman barghausen | ||
US215082A (en) * | 1879-05-06 | Improvement in type-writing machines | ||
US55060A (en) * | 1866-05-29 | Improvement in harvester-rakes | ||
US59240A (en) * | 1866-10-30 | Maeshall t | ||
US36294A (en) * | 1862-08-26 | Improved portable sugar-evaporatx | ||
US122622A (en) * | 1872-01-09 | Improvement in compartment-cars for railways | ||
US148897A (en) * | 1874-03-24 | Improvement in machines for pressing pantaloons | ||
US225226A (en) * | 1880-03-09 | Rotary engine | ||
US281219A (en) * | 1883-07-10 | Half to alonzo e | ||
US65567A (en) * | 1867-06-11 | Improved soeew machine | ||
US211173A (en) * | 1879-01-07 | Improvement in wagon-tracks for roads | ||
US574507A (en) * | 1897-01-05 | Account-keeping book | ||
US540732A (en) * | 1895-06-11 | Martin freund | ||
US56519A (en) * | 1866-07-24 | Improvement in clamps for holding saws | ||
US77953A (en) * | 1868-05-19 | b i c k e | ||
US681192A (en) * | 1900-11-19 | 1901-08-27 | Natural Food Company | Marking-machine. |
US678535A (en) * | 1901-02-02 | 1901-07-16 | Austen Bigg | Hoe. |
US911218A (en) * | 1908-02-17 | 1909-02-02 | Elias B Wrenn | Trace-holder. |
US1496918A (en) * | 1922-08-23 | 1924-06-10 | Frederick M Baldwin | Signaling device for vehicles |
US3773051A (en) | 1972-03-01 | 1973-11-20 | Research Corp | Method and apparatus for stimulation of body tissue |
US4146918A (en) * | 1978-01-18 | 1979-03-27 | Albert Tureck | Photographic flash reflector and diffuser system |
US4827935A (en) * | 1986-04-24 | 1989-05-09 | Purdue Research Foundation | Demand electroventilator |
US4830008A (en) * | 1987-04-24 | 1989-05-16 | Meer Jeffrey A | Method and system for treatment of sleep apnea |
US5329931A (en) * | 1989-02-21 | 1994-07-19 | William L. Clauson | Apparatus and method for automatic stimulation of mammals in response to blood gas analysis |
US5265604A (en) | 1990-05-14 | 1993-11-30 | Vince Dennis J | Demand - diaphragmatic pacing (skeletal muscle pressure modified) |
US5056519A (en) | 1990-05-14 | 1991-10-15 | Vince Dennis J | Unilateral diaphragmatic pacer |
US5281219A (en) | 1990-11-23 | 1994-01-25 | Medtronic, Inc. | Multiple stimulation electrodes |
US5211173A (en) | 1991-01-09 | 1993-05-18 | Medtronic, Inc. | Servo muscle control |
DE69209324T2 (en) | 1991-01-09 | 1996-11-21 | Medtronic Inc | Servo control for muscles |
US5190036A (en) * | 1991-02-28 | 1993-03-02 | Linder Steven H | Abdominal binder for effectuating cough stimulation |
US5146918A (en) * | 1991-03-19 | 1992-09-15 | Medtronic, Inc. | Demand apnea control of central and obstructive sleep apnea |
US5215082A (en) | 1991-04-02 | 1993-06-01 | Medtronic, Inc. | Implantable apnea generator with ramp on generator |
US5174287A (en) | 1991-05-28 | 1992-12-29 | Medtronic, Inc. | Airway feedback measurement system responsive to detected inspiration and obstructive apnea event |
US5233983A (en) | 1991-09-03 | 1993-08-10 | Medtronic, Inc. | Method and apparatus for apnea patient screening |
US5572543A (en) | 1992-04-09 | 1996-11-05 | Deutsch Aerospace Ag | Laser system with a micro-mechanically moved mirror |
US5423372A (en) * | 1993-12-27 | 1995-06-13 | Ford Motor Company | Joining sand cores for making castings |
US5524632A (en) | 1994-01-07 | 1996-06-11 | Medtronic, Inc. | Method for implanting electromyographic sensing electrodes |
US5800470A (en) | 1994-01-07 | 1998-09-01 | Medtronic, Inc. | Respiratory muscle electromyographic rate responsive pacemaker |
US5540733A (en) | 1994-09-21 | 1996-07-30 | Medtronic, Inc. | Method and apparatus for detecting and treating obstructive sleep apnea |
US5546952A (en) | 1994-09-21 | 1996-08-20 | Medtronic, Inc. | Method and apparatus for detection of a respiratory waveform |
US5540732A (en) | 1994-09-21 | 1996-07-30 | Medtronic, Inc. | Method and apparatus for impedance detecting and treating obstructive airway disorders |
US5540731A (en) | 1994-09-21 | 1996-07-30 | Medtronic, Inc. | Method and apparatus for pressure detecting and treating obstructive airway disorders |
US5549655A (en) | 1994-09-21 | 1996-08-27 | Medtronic, Inc. | Method and apparatus for synchronized treatment of obstructive sleep apnea |
US5485851A (en) | 1994-09-21 | 1996-01-23 | Medtronic, Inc. | Method and apparatus for arousal detection |
US5522862A (en) * | 1994-09-21 | 1996-06-04 | Medtronic, Inc. | Method and apparatus for treating obstructive sleep apnea |
US5483969A (en) * | 1994-09-21 | 1996-01-16 | Medtronic, Inc. | Method and apparatus for providing a respiratory effort waveform for the treatment of obstructive sleep apnea |
US5678535A (en) | 1995-04-21 | 1997-10-21 | Dimarco; Anthony Fortunato | Method and apparatus for electrical stimulation of the respiratory muscles to achieve artificial ventilation in a patient |
FR2739760B1 (en) * | 1995-10-11 | 1997-12-12 | Salomon Sa | METHOD AND DEVICE FOR HEATING AN INTERIOR SHOE LINING |
FR2739782B1 (en) * | 1995-10-13 | 1997-12-19 | Ela Medical Sa | ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR HEART STIMULATOR, WITH CONTROLLED OPERATION AND REDUCED CONSUMPTION |
US6006134A (en) * | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US5895360A (en) * | 1996-06-26 | 1999-04-20 | Medtronic, Inc. | Gain control for a periodic signal and method regarding same |
US5944680A (en) | 1996-06-26 | 1999-08-31 | Medtronic, Inc. | Respiratory effort detection method and apparatus |
US6021352A (en) | 1996-06-26 | 2000-02-01 | Medtronic, Inc, | Diagnostic testing methods and apparatus for implantable therapy devices |
US6132384A (en) | 1996-06-26 | 2000-10-17 | Medtronic, Inc. | Sensor, method of sensor implant and system for treatment of respiratory disorders |
US6099479A (en) | 1996-06-26 | 2000-08-08 | Medtronic, Inc. | Method and apparatus for operating therapy system |
SE9603841D0 (en) | 1996-10-18 | 1996-10-18 | Pacesetter Ab | A tissue stimulating apparatus |
US5830008A (en) | 1996-12-17 | 1998-11-03 | The Whitaker Corporation | Panel mountable connector |
US5876353A (en) * | 1997-01-31 | 1999-03-02 | Medtronic, Inc. | Impedance monitor for discerning edema through evaluation of respiratory rate |
US5797923A (en) | 1997-05-12 | 1998-08-25 | Aiyar; Harish | Electrode delivery instrument |
WO1999020339A1 (en) | 1997-10-17 | 1999-04-29 | Respironics, Inc. | Muscle stimulating device and method for diagnosing and treating a breathing disorder |
US6021362A (en) * | 1998-02-17 | 2000-02-01 | Maggard; Karl J. | Method and apparatus for dispensing samples and premiums |
US6269269B1 (en) | 1998-04-23 | 2001-07-31 | Medtronic Inc. | Method and apparatus for synchronized treatment of obstructive sleep apnea |
US6251126B1 (en) * | 1998-04-23 | 2001-06-26 | Medtronic Inc | Method and apparatus for synchronized treatment of obstructive sleep apnea |
CN103641885A (en) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | Protein purification by ion exchange chromatography |
AUPP366398A0 (en) | 1998-05-22 | 1998-06-18 | Resmed Limited | Ventilatory assistance for treatment of cardiac failure and cheyne-stokes breathing |
US6234985B1 (en) * | 1998-06-11 | 2001-05-22 | Cprx Llc | Device and method for performing cardiopulmonary resuscitation |
US6312399B1 (en) | 1998-06-11 | 2001-11-06 | Cprx, Llc | Stimulatory device and methods to enhance venous blood return during cardiopulmonary resuscitation |
US6463327B1 (en) | 1998-06-11 | 2002-10-08 | Cprx Llc | Stimulatory device and methods to electrically stimulate the phrenic nerve |
SE9802335D0 (en) | 1998-06-30 | 1998-06-30 | Siemens Elema Ab | Breathing Help System |
FR2780654B1 (en) | 1998-07-06 | 2000-12-01 | Ela Medical Sa | ACTIVE IMPLANTABLE MEDICAL DEVICE FOR ELECTROSTIMULATION TREATMENT OF SLEEP APNEA SYNDROME |
AU5130199A (en) * | 1998-07-27 | 2000-02-21 | Case Western Reserve University | Method and apparatus for closed-loop stimulation of the hypoglossal nerve in human patients to treat obstructive sleep apnea |
US6240316B1 (en) | 1998-08-14 | 2001-05-29 | Advanced Bionics Corporation | Implantable microstimulation system for treatment of sleep apnea |
US6212435B1 (en) * | 1998-11-13 | 2001-04-03 | Respironics, Inc. | Intraoral electromuscular stimulation device and method |
US7577475B2 (en) * | 1999-04-16 | 2009-08-18 | Cardiocom | System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus |
US6314324B1 (en) | 1999-05-05 | 2001-11-06 | Respironics, Inc. | Vestibular stimulation system and method |
US6512949B1 (en) * | 1999-07-12 | 2003-01-28 | Medtronic, Inc. | Implantable medical device for measuring time varying physiologic conditions especially edema and for responding thereto |
US6527729B1 (en) * | 1999-11-10 | 2003-03-04 | Pacesetter, Inc. | Method for monitoring patient using acoustic sensor |
US6600949B1 (en) * | 1999-11-10 | 2003-07-29 | Pacesetter, Inc. | Method for monitoring heart failure via respiratory patterns |
US6480733B1 (en) | 1999-11-10 | 2002-11-12 | Pacesetter, Inc. | Method for monitoring heart failure |
US6336903B1 (en) | 1999-11-16 | 2002-01-08 | Cardiac Intelligence Corp. | Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof |
US6752765B1 (en) * | 1999-12-01 | 2004-06-22 | Medtronic, Inc. | Method and apparatus for monitoring heart rate and abnormal respiration |
US6418346B1 (en) * | 1999-12-14 | 2002-07-09 | Medtronic, Inc. | Apparatus and method for remote therapy and diagnosis in medical devices via interface systems |
US20030127091A1 (en) * | 1999-12-15 | 2003-07-10 | Chang Yung Chi | Scientific respiration for self-health-care |
US6710094B2 (en) * | 1999-12-29 | 2004-03-23 | Styrochem Delaware, Inc. | Processes for preparing patterns for use in metal castings |
US6589188B1 (en) * | 2000-05-05 | 2003-07-08 | Pacesetter, Inc. | Method for monitoring heart failure via respiratory patterns |
US6735479B2 (en) | 2000-06-14 | 2004-05-11 | Medtronic, Inc. | Lifestyle management system |
US6666830B1 (en) | 2000-08-17 | 2003-12-23 | East River Ventures, Lp | System and method for detecting the onset of an obstructive sleep apnea event |
US6357438B1 (en) * | 2000-10-19 | 2002-03-19 | Mallinckrodt Inc. | Implantable sensor for proportional assist ventilation |
US6633779B1 (en) | 2000-11-27 | 2003-10-14 | Science Medicus, Inc. | Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms |
US6641542B2 (en) | 2001-04-30 | 2003-11-04 | Medtronic, Inc. | Method and apparatus to detect and treat sleep respiratory events |
US7206635B2 (en) | 2001-06-07 | 2007-04-17 | Medtronic, Inc. | Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
US6731984B2 (en) * | 2001-06-07 | 2004-05-04 | Medtronic, Inc. | Method for providing a therapy to a patient involving modifying the therapy after detecting an onset of sleep in the patient, and implantable medical device embodying same |
US6572949B1 (en) * | 2001-08-30 | 2003-06-03 | Carlton Paul Lewis | Paint mask and method of using |
FR2829917B1 (en) | 2001-09-24 | 2004-06-11 | Ela Medical Sa | ACTIVE MEDICAL DEVICE INCLUDING MEANS FOR DIAGNOSING THE RESPIRATORY PROFILE |
US6928324B2 (en) | 2002-02-14 | 2005-08-09 | Pacesetter, Inc. | Stimulation device for sleep apnea prevention, detection and treatment |
US6904320B2 (en) * | 2002-02-14 | 2005-06-07 | Pacesetter, Inc. | Sleep apnea therapy device using dynamic overdrive pacing |
US6999817B2 (en) | 2002-02-14 | 2006-02-14 | Packsetter, Inc. | Cardiac stimulation device including sleep apnea prevention and treatment |
US8391989B2 (en) * | 2002-12-18 | 2013-03-05 | Cardiac Pacemakers, Inc. | Advanced patient management for defining, identifying and using predetermined health-related events |
US20030195571A1 (en) | 2002-04-12 | 2003-10-16 | Burnes John E. | Method and apparatus for the treatment of central sleep apnea using biventricular pacing |
US20030204213A1 (en) | 2002-04-30 | 2003-10-30 | Jensen Donald N. | Method and apparatus to detect and monitor the frequency of obstructive sleep apnea |
US20030225339A1 (en) | 2002-05-06 | 2003-12-04 | Respironics Novametrix | Methods for inducing temporary changes in ventilation for estimation of hemodynamic performance |
US6881192B1 (en) * | 2002-06-12 | 2005-04-19 | Pacesetter, Inc. | Measurement of sleep apnea duration and evaluation of response therapies using duration metrics |
SE0202537D0 (en) * | 2002-08-28 | 2002-08-28 | Siemens Elema Ab | Nerve stimulation apparatus |
JP4095391B2 (en) * | 2002-09-24 | 2008-06-04 | キヤノン株式会社 | Position detection method |
JP4309111B2 (en) * | 2002-10-02 | 2009-08-05 | 株式会社スズケン | Health management system, activity state measuring device and data processing device |
US6945939B2 (en) * | 2002-10-18 | 2005-09-20 | Pacesetter, Inc. | Hemodynamic analysis |
US7277757B2 (en) * | 2002-10-31 | 2007-10-02 | Medtronic, Inc. | Respiratory nerve stimulation |
US7252640B2 (en) * | 2002-12-04 | 2007-08-07 | Cardiac Pacemakers, Inc. | Detection of disordered breathing |
US8672852B2 (en) * | 2002-12-13 | 2014-03-18 | Intercure Ltd. | Apparatus and method for beneficial modification of biorhythmic activity |
US7160252B2 (en) * | 2003-01-10 | 2007-01-09 | Medtronic, Inc. | Method and apparatus for detecting respiratory disturbances |
US7438686B2 (en) * | 2003-01-10 | 2008-10-21 | Medtronic, Inc. | Apparatus and method for monitoring for disordered breathing |
US7025730B2 (en) * | 2003-01-10 | 2006-04-11 | Medtronic, Inc. | System and method for automatically monitoring and delivering therapy for sleep-related disordered breathing |
US20050020240A1 (en) * | 2003-02-07 | 2005-01-27 | Darin Minter | Private wireless network |
US7840270B2 (en) * | 2003-07-23 | 2010-11-23 | Synapse Biomedical, Inc. | System and method for conditioning a diaphragm of a patient |
EP1660177A4 (en) * | 2003-07-23 | 2010-03-03 | Univ Cleveland Hospitals | Mapping probe system for neuromuscular electrical stimulation apparatus |
US7396333B2 (en) * | 2003-08-18 | 2008-07-08 | Cardiac Pacemakers, Inc. | Prediction of disordered breathing |
US7532934B2 (en) * | 2003-09-18 | 2009-05-12 | Cardiac Pacemakers, Inc. | Snoring detection system and method |
US7469697B2 (en) * | 2003-09-18 | 2008-12-30 | Cardiac Pacemakers, Inc. | Feedback system and method for sleep disordered breathing therapy |
US7720541B2 (en) * | 2003-08-18 | 2010-05-18 | Cardiac Pacemakers, Inc. | Adaptive therapy for disordered breathing |
US7591265B2 (en) * | 2003-09-18 | 2009-09-22 | Cardiac Pacemakers, Inc. | Coordinated use of respiratory and cardiac therapies for sleep disordered breathing |
US7757690B2 (en) * | 2003-09-18 | 2010-07-20 | Cardiac Pacemakers, Inc. | System and method for moderating a therapy delivered during sleep using physiologic data acquired during non-sleep |
US7680537B2 (en) * | 2003-08-18 | 2010-03-16 | Cardiac Pacemakers, Inc. | Therapy triggered by prediction of disordered breathing |
US7664546B2 (en) * | 2003-09-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Posture detection system and method |
US7510531B2 (en) * | 2003-09-18 | 2009-03-31 | Cardiac Pacemakers, Inc. | System and method for discrimination of central and obstructive disordered breathing events |
US7610094B2 (en) * | 2003-09-18 | 2009-10-27 | Cardiac Pacemakers, Inc. | Synergistic use of medical devices for detecting medical disorders |
US7787946B2 (en) * | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
US7468040B2 (en) * | 2003-09-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Methods and systems for implantably monitoring external breathing therapy |
US7662101B2 (en) * | 2003-09-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Therapy control based on cardiopulmonary status |
EP1512430B1 (en) * | 2003-09-02 | 2008-02-13 | Biotronik GmbH & Co. KG | Device for sleep-apnea treatment |
US20050055060A1 (en) * | 2003-09-05 | 2005-03-10 | Steve Koh | Determination of respiratory characteristics from AV conduction intervals |
US6905788B2 (en) * | 2003-09-12 | 2005-06-14 | Eastman Kodak Company | Stabilized OLED device |
US20050065563A1 (en) * | 2003-09-23 | 2005-03-24 | Avram Scheiner | Paced ventilation therapy by an implantable cardiac device |
US7979128B2 (en) * | 2003-10-15 | 2011-07-12 | Rmx, Llc | Device and method for gradually controlling breathing |
US8140164B2 (en) * | 2003-10-15 | 2012-03-20 | Rmx, Llc | Therapeutic diaphragm stimulation device and method |
US20060167523A1 (en) * | 2003-10-15 | 2006-07-27 | Tehrani Amir J | Device and method for improving upper airway functionality |
US20120158091A1 (en) * | 2003-10-15 | 2012-06-21 | Rmx, Llc | Therapeutic diaphragm stimulation device and method |
US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
US8265759B2 (en) | 2003-10-15 | 2012-09-11 | Rmx, Llc | Device and method for treating disorders of the cardiovascular system or heart |
US8160711B2 (en) | 2003-10-15 | 2012-04-17 | Rmx, Llc | Multimode device and method for controlling breathing |
US7970475B2 (en) * | 2003-10-15 | 2011-06-28 | Rmx, Llc | Device and method for biasing lung volume |
US20080161878A1 (en) | 2003-10-15 | 2008-07-03 | Tehrani Amir J | Device and method to for independently stimulating hemidiaphragms |
US8244358B2 (en) * | 2003-10-15 | 2012-08-14 | Rmx, Llc | Device and method for treating obstructive sleep apnea |
US9259573B2 (en) * | 2003-10-15 | 2016-02-16 | Rmx, Llc | Device and method for manipulating exhalation |
US6964641B2 (en) * | 2003-12-24 | 2005-11-15 | Medtronic, Inc. | Implantable medical device with sleep disordered breathing monitoring |
US7519425B2 (en) * | 2004-01-26 | 2009-04-14 | Pacesetter, Inc. | Tiered therapy for respiratory oscillations characteristic of Cheyne-Stokes respiration |
WO2005074361A2 (en) | 2004-02-05 | 2005-08-18 | Earlysense Ltd. | Techniques for prediction and monitoring of respiration-manifested clinical episodes |
US7070568B1 (en) * | 2004-03-02 | 2006-07-04 | Pacesetter, Inc. | System and method for diagnosing and tracking congestive heart failure based on the periodicity of Cheyne-Stokes Respiration using an implantable medical device |
DE102004016985B4 (en) | 2004-04-07 | 2010-07-22 | Pari Pharma Gmbh | Aerosol generating device and inhalation device |
US7245971B2 (en) | 2004-04-21 | 2007-07-17 | Pacesetter, Inc. | System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device |
US7082331B1 (en) * | 2004-04-21 | 2006-07-25 | Pacesetter, Inc. | System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device |
JP4396380B2 (en) | 2004-04-26 | 2010-01-13 | アイシン・エィ・ダブリュ株式会社 | Traffic information transmission device and transmission method |
US7153271B2 (en) | 2004-05-20 | 2006-12-26 | Airmatrix Technologies, Inc. | Method and system for diagnosing central versus obstructive apnea |
US20060058852A1 (en) * | 2004-09-10 | 2006-03-16 | Steve Koh | Multi-variable feedback control of stimulation for inspiratory facilitation |
US7678116B2 (en) * | 2004-12-06 | 2010-03-16 | Dfine, Inc. | Bone treatment systems and methods |
US20080021506A1 (en) * | 2006-05-09 | 2008-01-24 | Massachusetts General Hospital | Method and device for the electrical treatment of sleep apnea and snoring |
US8280513B2 (en) | 2006-12-22 | 2012-10-02 | Rmx, Llc | Device and method to treat flow limitations |
-
2003
- 2003-10-15 US US10/686,891 patent/US8467876B2/en active Active
-
2004
- 2004-10-15 US US10/966,421 patent/US8255056B2/en active Active
- 2004-10-15 WO PCT/US2004/034103 patent/WO2005037366A1/en active Application Filing
- 2004-10-15 US US10/966,484 patent/US20050085869A1/en not_active Abandoned
- 2004-10-15 US US10/966,474 patent/US8412331B2/en active Active
- 2004-10-15 DE DE112004001953T patent/DE112004001953T5/en not_active Withdrawn
- 2004-10-15 DE DE112004001954.0T patent/DE112004001954B4/en not_active Expired - Fee Related
- 2004-10-15 WO PCT/US2004/034213 patent/WO2005037174A2/en active Application Filing
- 2004-10-15 WO PCT/US2004/034170 patent/WO2005037220A2/en active Application Filing
- 2004-10-15 US US10/966,472 patent/US8200336B2/en active Active
- 2004-10-15 WO PCT/US2004/033850 patent/WO2005037172A2/en active Application Filing
- 2004-10-15 US US10/966,487 patent/US20050085734A1/en not_active Abandoned
- 2004-10-15 WO PCT/US2004/034212 patent/WO2005037173A2/en active Application Filing
- 2004-10-15 DE DE112004001957T patent/DE112004001957T5/en not_active Withdrawn
- 2004-10-15 WO PCT/US2004/034211 patent/WO2005037077A2/en active Application Filing
-
2005
- 2005-10-11 US US11/246,439 patent/US20060030894A1/en not_active Abandoned
- 2005-10-13 US US11/249,718 patent/US8348941B2/en active Active
-
2006
- 2006-09-25 US US11/526,949 patent/US8509901B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/981,831 patent/US20080183240A1/en not_active Abandoned
- 2007-10-31 US US11/981,727 patent/US20080183239A1/en not_active Abandoned
- 2007-10-31 US US11/981,800 patent/US8116872B2/en active Active
-
2008
- 2008-04-01 US US12/080,133 patent/US20080188903A1/en not_active Abandoned
-
2013
- 2013-03-26 US US13/851,003 patent/US20130296973A1/en not_active Abandoned
- 2013-06-11 US US13/915,316 patent/US20130296964A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7117032B2 (en) * | 1999-03-01 | 2006-10-03 | Quantum Intech, Inc. | Systems and methods for facilitating physiological coherence using respiration training |
US6415183B1 (en) * | 1999-12-09 | 2002-07-02 | Cardiac Pacemakers, Inc. | Method and apparatus for diaphragmatic pacing |
US20050261747A1 (en) * | 2003-05-16 | 2005-11-24 | Schuler Eleanor L | Method and system to control respiration by means of neuro-electrical coded signals |
US20060122661A1 (en) * | 2004-12-03 | 2006-06-08 | Mandell Lee J | Diaphragmatic pacing with activity monitor adjustment |
US20060224211A1 (en) * | 2005-03-31 | 2006-10-05 | Durand Dominique M | Method of treating obstructive sleep apnea using electrical nerve stimulation |
US20060282131A1 (en) * | 2005-06-13 | 2006-12-14 | Cardiac Pacemakers, Inc. | System for neural control of respiration |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8509901B2 (en) | 2003-10-15 | 2013-08-13 | Rmx, Llc | Device and method for adding to breathing |
US20060036294A1 (en) * | 2003-10-15 | 2006-02-16 | Tehrani Amir J | Patient compliance management device and method |
US20050085868A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | Breathing therapy device and method |
US9370657B2 (en) | 2003-10-15 | 2016-06-21 | Rmx, Llc | Device for manipulating tidal volume and breathing entrainment |
US20050085867A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | System and method for diaphragm stimulation |
US9259573B2 (en) | 2003-10-15 | 2016-02-16 | Rmx, Llc | Device and method for manipulating exhalation |
US20050085866A1 (en) * | 2003-10-15 | 2005-04-21 | Tehrani Amir J. | Breathing disorder and precursor predictor and therapy delivery device and method |
US8200336B2 (en) | 2003-10-15 | 2012-06-12 | Rmx, Llc | System and method for diaphragm stimulation |
US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
US8412331B2 (en) | 2003-10-15 | 2013-04-02 | Rmx, Llc | Breathing therapy device and method |
US8255056B2 (en) | 2003-10-15 | 2012-08-28 | Rmx, Llc | Breathing disorder and precursor predictor and therapy delivery device and method |
US8265759B2 (en) | 2003-10-15 | 2012-09-11 | Rmx, Llc | Device and method for treating disorders of the cardiovascular system or heart |
US8348941B2 (en) | 2003-10-15 | 2013-01-08 | Rmx, Llc | Demand-based system for treating breathing disorders |
US8335567B2 (en) | 2003-10-15 | 2012-12-18 | Rmx, Llc | Multimode device and method for controlling breathing |
US8244359B2 (en) | 2005-11-18 | 2012-08-14 | Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US20070118183A1 (en) * | 2005-11-18 | 2007-05-24 | Mark Gelfand | System and method to modulate phrenic nerve to prevent sleep apnea |
US10518090B2 (en) | 2005-11-18 | 2019-12-31 | Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US11305119B2 (en) | 2005-11-18 | 2022-04-19 | Zoll Respicardia, Inc. | System and method to modulate phrenic nerve to prevent sleep apnea |
US10406366B2 (en) | 2006-11-17 | 2019-09-10 | Respicardia, Inc. | Transvenous phrenic nerve stimulation system |
US8280513B2 (en) | 2006-12-22 | 2012-10-02 | Rmx, Llc | Device and method to treat flow limitations |
US8909341B2 (en) | 2007-01-22 | 2014-12-09 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US9744351B1 (en) | 2007-01-22 | 2017-08-29 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US10300270B2 (en) | 2007-01-22 | 2019-05-28 | Respicardia, Inc. | Device and method for the treatment of breathing disorders and cardiac disorders |
US20080208282A1 (en) * | 2007-01-22 | 2008-08-28 | Mark Gelfand | Device and method for the treatment of breathing disorders and cardiac disorders |
US9968785B2 (en) | 2007-01-29 | 2018-05-15 | Lungpacer Medical, Inc. | Transvascular nerve stimulation apparatus and methods |
US9950167B2 (en) | 2007-01-29 | 2018-04-24 | Lungpacer Medical, Inc. | Transvascular nerve stimulation apparatus and methods |
US10022546B2 (en) | 2007-01-29 | 2018-07-17 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US11027130B2 (en) | 2007-01-29 | 2021-06-08 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10864374B2 (en) | 2007-01-29 | 2020-12-15 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US9566436B2 (en) | 2007-01-29 | 2017-02-14 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
US10792499B2 (en) | 2007-01-29 | 2020-10-06 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10561843B2 (en) | 2007-01-29 | 2020-02-18 | Lungpacer Medical, Inc. | Transvascular nerve stimulation apparatus and methods |
US10765867B2 (en) | 2007-01-29 | 2020-09-08 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US9987488B1 (en) | 2007-06-27 | 2018-06-05 | Respicardia, Inc. | Detecting and treating disordered breathing |
US11305114B2 (en) | 2007-06-27 | 2022-04-19 | Zoll Respicardia, Inc. | Detecting and treating disordered breathing |
US20140051938A1 (en) * | 2007-11-26 | 2014-02-20 | David Brian Goldstein | Device to detect and treat Apneas and Hypopnea |
US11089994B2 (en) | 2007-11-26 | 2021-08-17 | Whispersom Corporation | Device to detect and treat apneas and hypopnea |
US11813078B2 (en) | 2007-11-26 | 2023-11-14 | Whispersom Corporation | Device to detect and treat apneas and hypopnea |
US9295846B2 (en) | 2008-02-07 | 2016-03-29 | Respicardia, Inc. | Muscle and nerve stimulation |
US11389648B2 (en) | 2008-02-07 | 2022-07-19 | Zoll Respicardia, Inc. | Transvascular medical lead |
US11865333B2 (en) | 2008-02-07 | 2024-01-09 | Zoll Respicardia, Inc. | Transvascular medical lead |
US8433412B1 (en) | 2008-02-07 | 2013-04-30 | Respicardia, Inc. | Muscle and nerve stimulation |
US9649458B2 (en) | 2008-09-30 | 2017-05-16 | Covidien Lp | Breathing assistance system with multiple pressure sensors |
US11065443B2 (en) | 2009-09-10 | 2021-07-20 | Zoll Respicardia, Inc. | Respiratory rectification |
US8233987B2 (en) | 2009-09-10 | 2012-07-31 | Respicardia, Inc. | Respiratory rectification |
US9999768B2 (en) * | 2009-09-10 | 2018-06-19 | Respicardia, Inc. | Respiratory rectification |
US11883659B2 (en) | 2009-09-10 | 2024-01-30 | Zoll Respicardia, Inc. | Systems for treating disordered breathing by comparing stimulated and unstimulated breathing |
US20110060380A1 (en) * | 2009-09-10 | 2011-03-10 | Mark Gelfand | Respiratory rectification |
US20130158625A1 (en) * | 2009-09-10 | 2013-06-20 | Respicardia, Inc. | Respiratory Rectification |
US20130247914A1 (en) * | 2010-11-23 | 2013-09-26 | Koninklijke Philips Electronics N.V. | Obesity hypventilation syndrome treatment system and method |
US9717868B2 (en) * | 2010-11-23 | 2017-08-01 | Koninklijke Philips N.V. | Obesity hypventilation syndrome treatment system and method |
US20130053717A1 (en) * | 2011-08-30 | 2013-02-28 | Nellcor Puritan Bennett Llc | Automatic ventilator challenge to induce spontaneous breathing efforts |
US11497869B2 (en) | 2011-12-07 | 2022-11-15 | Covidien Lp | Methods and systems for adaptive base flow |
US10543327B2 (en) | 2011-12-07 | 2020-01-28 | Covidien Lp | Methods and systems for adaptive base flow |
US9364624B2 (en) | 2011-12-07 | 2016-06-14 | Covidien Lp | Methods and systems for adaptive base flow |
US11833297B2 (en) | 2011-12-31 | 2023-12-05 | Covidien Lp | Methods and systems for adaptive base flow and leak compensation |
US9498589B2 (en) | 2011-12-31 | 2016-11-22 | Covidien Lp | Methods and systems for adaptive base flow and leak compensation |
US10709854B2 (en) | 2011-12-31 | 2020-07-14 | Covidien Lp | Methods and systems for adaptive base flow and leak compensation |
US11369787B2 (en) | 2012-03-05 | 2022-06-28 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10512772B2 (en) | 2012-03-05 | 2019-12-24 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
US10029057B2 (en) | 2012-03-30 | 2018-07-24 | Covidien Lp | Methods and systems for triggering with unknown base flow |
US8844526B2 (en) | 2012-03-30 | 2014-09-30 | Covidien Lp | Methods and systems for triggering with unknown base flow |
US10406367B2 (en) | 2012-06-21 | 2019-09-10 | Lungpacer Medical Inc. | Transvascular diaphragm pacing system and methods of use |
US9776005B2 (en) | 2012-06-21 | 2017-10-03 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US11357985B2 (en) | 2012-06-21 | 2022-06-14 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US10561844B2 (en) | 2012-06-21 | 2020-02-18 | Lungpacer Medical Inc. | Diaphragm pacing systems and methods of use |
US10589097B2 (en) | 2012-06-21 | 2020-03-17 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems and methods of use |
US9981096B2 (en) | 2013-03-13 | 2018-05-29 | Covidien Lp | Methods and systems for triggering with unknown inspiratory flow |
US9931504B2 (en) | 2013-11-22 | 2018-04-03 | Lungpacer Medical, Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US9545511B2 (en) | 2013-11-22 | 2017-01-17 | Simon Fraser University | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10035017B2 (en) | 2013-11-22 | 2018-07-31 | Lungpacer Medical, Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US11707619B2 (en) | 2013-11-22 | 2023-07-25 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US10391314B2 (en) | 2014-01-21 | 2019-08-27 | Lungpacer Medical Inc. | Systems and related methods for optimization of multi-electrode nerve pacing |
US11311730B2 (en) | 2014-01-21 | 2022-04-26 | Lungpacer Medical Inc. | Systems and related methods for optimization of multi-electrode nerve pacing |
US9597509B2 (en) | 2014-01-21 | 2017-03-21 | Simon Fraser University | Systems and related methods for optimization of multi-electrode nerve pacing |
US10864336B2 (en) | 2014-08-15 | 2020-12-15 | Covidien Lp | Methods and systems for breath delivery synchronization |
US9808591B2 (en) | 2014-08-15 | 2017-11-07 | Covidien Lp | Methods and systems for breath delivery synchronization |
US11497915B2 (en) | 2014-08-26 | 2022-11-15 | Rmx, Llc | Devices and methods for reducing intrathoracic pressure |
US10857363B2 (en) | 2014-08-26 | 2020-12-08 | Rmx, Llc | Devices and methods for reducing intrathoracic pressure |
US11712174B2 (en) | 2014-10-27 | 2023-08-01 | Covidien Lp | Ventilation triggering |
US9950129B2 (en) | 2014-10-27 | 2018-04-24 | Covidien Lp | Ventilation triggering using change-point detection |
US10940281B2 (en) | 2014-10-27 | 2021-03-09 | Covidien Lp | Ventilation triggering |
US9925346B2 (en) | 2015-01-20 | 2018-03-27 | Covidien Lp | Systems and methods for ventilation with unknown exhalation flow |
US11844605B2 (en) | 2016-11-10 | 2023-12-19 | The Research Foundation For Suny | System, method and biomarkers for airway obstruction |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US11883658B2 (en) | 2017-06-30 | 2024-01-30 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US11090489B2 (en) | 2017-08-02 | 2021-08-17 | Lungpacer Medical, Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10039920B1 (en) | 2017-08-02 | 2018-08-07 | Lungpacer Medical, Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10926087B2 (en) | 2017-08-02 | 2021-02-23 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US11944810B2 (en) | 2017-08-04 | 2024-04-02 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US11717673B2 (en) | 2018-11-08 | 2023-08-08 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US10987511B2 (en) | 2018-11-08 | 2021-04-27 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11890462B2 (en) | 2018-11-08 | 2024-02-06 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
US11357979B2 (en) | 2019-05-16 | 2022-06-14 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
US11266838B1 (en) | 2019-06-21 | 2022-03-08 | Rmx, Llc | Airway diagnostics utilizing phrenic nerve stimulation device and method |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8412331B2 (en) | Breathing therapy device and method | |
US20220176119A1 (en) | System and method to modulate phrenic nerve to prevent sleep apnea | |
JP5389650B2 (en) | A system for neural stimulation using feedback by respiration | |
JP5231418B2 (en) | System for neural stimulation during respiratory disorders | |
US7596413B2 (en) | Coordinated therapy for disordered breathing including baroreflex modulation | |
US7747323B2 (en) | Adaptive baroreflex stimulation therapy for disordered breathing | |
US8140164B2 (en) | Therapeutic diaphragm stimulation device and method | |
US8321022B2 (en) | Adaptive therapy for disordered breathing | |
US20090024176A1 (en) | Methods and devices for producing respiratory sinus arrhythmia | |
US20120158091A1 (en) | Therapeutic diaphragm stimulation device and method | |
US20120010677A1 (en) | Acquiring nerve activity from carotid body and/or sinus | |
US20220134101A1 (en) | Sleep apnea therapy | |
US11266838B1 (en) | Airway diagnostics utilizing phrenic nerve stimulation device and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RMX, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSPIRATION MEDICAL, INC.;REEL/FRAME:023158/0656 Effective date: 20070831 Owner name: INSPIRATION MEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TEHRANI, AMIR J.;LIGON, DAVID;REEL/FRAME:023158/0508 Effective date: 20050110 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |